<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Omeprazole: Pediatric drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Omeprazole: Pediatric drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Omeprazole: Pediatric drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_general" data-topicid="9718" href="/d/html/9718.html" rel="external">see "Omeprazole: Drug information"</a> and <a class="drug drug_patient" data-topicid="11813" href="/d/html/11813.html" rel="external">see "Omeprazole: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F203557"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Acid Reducer [OTC];</li>
<li>PriLOSEC;</li>
<li>PriLOSEC OTC [OTC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867757"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Omeprazole;</li>
<li>BIO-Omeprazole;</li>
<li>JAMP-Omeprazole DR;</li>
<li>Losec;</li>
<li>Losec Mups;</li>
<li>NAT-Omeprazole DR;</li>
<li>NRA-Omeprazole [DSC];</li>
<li>Omeprazole-20;</li>
<li>PMS-Omeprazole [DSC];</li>
<li>Priva-Omeprazole [DSC];</li>
<li>RAN-Omeprazole [DSC];</li>
<li>RIVA-Omeprazole DR;</li>
<li>SANDOZ Omeprazole;</li>
<li>SANDOZ Omperazole;</li>
<li>TEVA-Omeprazole</li></ul></div>
<div class="list_set htclist drugH1Div drugBrandNames" id="F1060710"><span class="drugH1">Therapeutic Category</span>
<ul>
<li>
<span class="list-set-name">Gastric Acid Secretion Inhibitor</span>;</li>
<li>
<span class="list-set-name">Gastrointestinal Agent, Gastric or Duodenal Ulcer Treatment</span>;</li>
<li>
<span class="list-set-name">Proton Pump Inhibitor</span></li></ul></div>
<div class="block don drugH1Div" id="F53462526"><span class="drugH1">Dosing: Neonatal</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d70158bf-5a0b-453d-9ae1-580dc5459992">Gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:0em;display:inline">
<b>Gastroesophageal reflux disease (GERD):</b>
<b>Note:</b> Routine use is not recommended in preterm neonates (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29915158']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29915158'])">Ref</a></span>). Limited data available: Term and preterm neonates: Oral: 0.7 mg/kg/dose once daily reduced the percentage of time gastric and esophageal pH &lt;4, as well as the number of reflux episodes in 10 infants (mean PMA: 36.1 weeks; range: 34 to 40 weeks) in a randomized, double-blind, placebo-controlled trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17204951']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17204951'])">Ref</a></span>). In a dose-finding study of neonates with PMA ≥35 weeks (n=54, GA: 24 to 41 weeks, PNA: 6 to 85 days), higher doses of 1 to 2.5 mg/kg once daily were reported. Based on intraesophageal pH monitoring, this study found that neonates with GA &lt;32 weeks generally required doses up to 2.5 mg/kg/day and neonates with GA ≥32 weeks required lower doses of 1 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28002471']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28002471'])">Ref</a></span>).</p></div>
</div>
</div>
<div class="block dop drugH1Div" id="F203584"><span class="drugH1">Dosing: Pediatric</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ce47ce73-fbfd-4c54-81d2-f67675bc530e">Erosive esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Erosive esophagitis:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Treatment: </i>
<b>Note:</b> Duration of therapy is dependent on age: Infant duration is up to 6 weeks and children and adolescent duration is 4 to 8 weeks. In children and adolescents with no response at 8 weeks, treatment may continue to an additional 4 weeks. For recurrence of erosive esophagitis or gastroesophageal reflux disease (GERD) symptoms (eg, heartburn), an additional 4- to 8-week course may be considered.</p>
<p style="text-indent:-2em;margin-left:6em;">Infants, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:8em;">3 to &lt;5 kg: 2.5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">5 kg to &lt;10 kg: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">10 kg to &lt;20 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:8em;">≥20 kg: 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance of healing: </i>Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">5 kg to &lt;10 kg: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">10 kg to &lt;20 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥20 kg: 20 mg once daily.</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="d70158bf-5a0b-453d-9ae1-580dc5459992">Gastroesophageal reflux disease</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease (GERD):</b>
<b>Note: </b>Guidelines recommend a 4- to 8-week treatment course; if improvement seen after 4 to 8 weeks, consider possible wean; if no response after 4 to 8 weeks, reevaluate diagnosis and consider referral to pediatric GI specialist (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470322'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Fixed dosing: Children and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:6em;">5 kg to &lt;10 kg: 5 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">10 kg to &lt;20 kg: 10 mg once daily.</p>
<p style="text-indent:-2em;margin-left:6em;">≥20 kg: 20 mg once daily.</p>
<p style="text-indent:-2em;margin-left:4em;">Weight-based dosing: Infants, Children, and Adolescents: Oral: 0.7 to 4 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629618','lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629618','lexi-content-ref-29470322'])">Ref</a></span>); the dose most frequently reported to provide healing of esophagitis and relief of GERD symptoms is 1 mg/kg/day (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11394727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11394727'])">Ref</a></span>); maximum daily dose: 40 mg/<b>day</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29470322']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29470322'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori</i> eradication</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28541262']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28541262'])">Ref</a></span>): Oral: Children and Adolescents: <b>Note:</b> Usual duration of therapy is 14 days as part of triple therapy; use in combination with 2 antimicrobials (eg, clarithromycin, metronidazole, amoxicillin); preferred agents determined by susceptibility. Bismuth may be added to regimens as an alternative if resistance is present or susceptibility is unknown.</p>
<p style="text-indent:-2em;margin-left:4em;">15 to &lt;25 kg: 20 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">25 to 34 kg: 30 mg twice daily.</p>
<p style="text-indent:-2em;margin-left:4em;">&gt;34 kg: 40 mg twice daily.</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;">
<b>Discontinuation of therapy:</b> Oral: Based on experience in adults, some experts recommend a step-down approach in order to avoid worsening or rebound symptoms. One recommendation is to decrease the dose by 50% over 2 to 4 weeks. If the patient is already on the lowest possible dose, alternate day therapy may be considered. If symptoms worsen during treatment or after discontinuation, patient should be reevaluated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29767318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29767318'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dorp drugH1Div" id="F51150889"><span class="drugH1">Dosing: Kidney Impairment: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Infants, Children, and Adolescents: Oral:</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Mild to severe:</b> No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Hemodialysis, intermittent:</b> Poorly dialyzed. There are no dosing adjustments provided in the manufacturer's labeling; however, based on adult data, no supplemental dosage or adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4065187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4065187'])">Ref</a></span>).</p></div>
<div class="block dohp drugH1Div" id="F51150890"><span class="drugH1">Dosing: Hepatic Impairment: Pediatric</span>
<p style="text-indent:0em;display:inline">Infants, Children, and Adolescents: There are no dosage adjustments provided in the manufacturer's labeling. However, based on increased bioavailability, dosage adjustment should be considered, especially for maintenance healing of erosive esophagitis. Specific guidelines are not available.</p></div>
<div class="block doa drugH1Div" id="F203562"><span class="drugH1">Dosing: Adult</span><p>(For additional information <a class="drug drug_general" data-topicid="9718" href="/d/html/9718.html" rel="external">see "Omeprazole: Drug information"</a>)</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Dosage guidance:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Clinical considerations</b>: Avoid coadministration with other antisecretory agents due to decreased acid-inhibitory effects. If another antisecretory agent is needed, allow a sufficient time interval between administration (ie, morning omeprazole and bedtime H<sub>2</sub>RA) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381','lexi-content-ref-Wolfe.2020','lexi-content-ref-10868896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381','lexi-content-ref-Wolfe.2020','lexi-content-ref-10868896'])">Ref</a></span>).</p>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="b9e2fd80-308d-4eb0-a497-00b0397cb8b3">Aspiration prophylaxis in patients undergoing anesthesia</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Aspiration prophylaxis in patients undergoing anesthesia (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>May be considered in patients at high risk for aspiration (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28045707']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28045707'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 40 mg given the night before surgery and 40 mg given the morning of surgery (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-7999487','lexi-content-ref-2386275','lexi-content-ref-8652333','lexi-content-ref-22289674']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-7999487','lexi-content-ref-2386275','lexi-content-ref-8652333','lexi-content-ref-22289674'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="60677fdf-855d-4121-a2fd-089025faf2ea">Barrett esophagus</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Barrett esophagus (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg once daily; may increase the dose (eg, to 20 mg twice daily) if needed to eliminate gastroesophageal reflux disease symptoms or heal reflux esophagitis. Long-term maintenance therapy is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-9768533','lexi-content-ref-26526079','lexi-content-ref-Spechler.2019','lexi-content-ref-25162890']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-9768533','lexi-content-ref-26526079','lexi-content-ref-Spechler.2019','lexi-content-ref-25162890'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="4d2394bf-599a-4605-a6c3-07d160c2d0c7">Dyspepsia, functional</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Dyspepsia, functional (idiopathic or non-ulcer) (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients who test negative for <i>H. pylori</i> infection or have persistent symptoms following <i>H. pylori</i> eradication (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28631728','lexi-content-ref-Longstreth.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28631728','lexi-content-ref-Longstreth.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg once daily for a 4- to 8-week trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28271513','lexi-content-ref-15984968']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28271513','lexi-content-ref-15984968'])">Ref</a></span>); can be continued for a longer duration in patients with symptom improvement. Some experts recommend attempting to discontinue every 6 to 12 months to minimize the long-term risk of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Longstreth.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Longstreth.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="c7eb41f5-ab77-43d2-b32d-436b6b436e7f">Eosinophilic esophagitis</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Eosinophilic esophagitis (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg twice daily for an 8-week trial (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32677040','lexi-content-ref-26247167','lexi-content-ref-24117619']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32677040','lexi-content-ref-26247167','lexi-content-ref-24117619'])">Ref</a></span>). Once 8-week trial is complete and remission is achieved, the dose may be gradually lowered to an individualized maintenance level (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32677040']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32677040'])">Ref</a></span>). Some experts initiate with 20 mg once daily and increase to twice daily dosing after 4 weeks if symptoms fail to improve (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bonis.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bonis.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="af13b8bc-31d9-4d53-ade6-d0f129e2f0f1">Gastroesophageal reflux disease, erosive or nonerosive</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Gastroesophageal reflux disease, erosive or nonerosive:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Initial therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Mild/intermittent disease (&lt;2 episodes/week) and no evidence of erosive esophagitis: </b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Note: </b>Some experts reserve proton pump inhibitors (PPIs) for patients who have residual acid reflux symptoms despite twice-daily H<sub>2</sub>RA (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 10 mg once daily; can increase to 20 mg once daily after 4 to 8 weeks if necessary. Discontinue once asymptomatic for 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10201459','lexi-content-ref-Kahrilas.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10201459','lexi-content-ref-Kahrilas.2020'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Severe and/or frequent symptoms (≥2 episodes/week) and/or erosive esophagitis:</b></p>
<p style="text-indent:-2em;margin-left:8em;">
<b>Oral:</b> 20 to 40 mg once daily; once symptoms are controlled, continue for at least 8 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2020','lexi-content-ref-PAD.2015','lexi-content-ref-30094626','lexi-content-ref-10868896']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2020','lexi-content-ref-PAD.2015','lexi-content-ref-30094626','lexi-content-ref-10868896'])">Ref</a></span>). Subsequently, patients without erosive esophagitis or Barrett esophagus can taper to the lowest dose necessary to control symptoms (and/or switch to an H<sub>2</sub>RA blocker) then discontinue acid suppression once asymptomatic. Patients with erosive esophagitis or Barrett esophagus should continue long-term maintenance therapy with 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Kahrilas.2020','lexi-content-ref-12095478','lexi-content-ref-Spechler.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Kahrilas.2020','lexi-content-ref-12095478','lexi-content-ref-Spechler.2019'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>
<i>Residual symptoms despite 40 mg once daily therapy:</i></b></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> Referral to a specialist is recommended.</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> Options include splitting the dose to 20 mg twice daily, increasing the dose to 40 mg twice daily, or switching to another PPI (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381','lexi-content-ref-Fass.2019','lexi-content-ref-19821323']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381','lexi-content-ref-Fass.2019','lexi-content-ref-19821323'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>
<b>OTC labeling (patient-guided therapy):</b></i>Heartburn, frequent symptoms (≥2 episodes/week):</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 20 mg once daily for 14 days (maximum: 20 mg/day); may repeat a 14-day course every 4 months if needed. Seek medical referral if symptoms do not resolve within 14 days of treatment; do not take for &gt;14 days or more often than every 4 months unless directed by a physician (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Manu.1'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="8b8d4809-3f39-4624-a159-df262570daf3">
<i>Helicobacter pylori</i> eradication</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Helicobacter pylori </i>eradication:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg or 40 mg twice daily as part of an appropriate combination regimen with antibiotics. Dose depends on the selected regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28071659','lexi-content-ref-Crowe.2020','lexi-content-ref-27102658']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28071659','lexi-content-ref-Crowe.2020','lexi-content-ref-27102658'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="e2fb2a31-e99b-4da1-8e12-14220432720a">Nonsteroidal anti-inflammatory drug–induced ulcers, primary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Nonsteroidal anti-inflammatory drug (including aspirin)–induced ulcers, primary prevention (off-label use): </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note: </b>For select patients at moderate or high risk for GI toxicity. These include patients with a history of GI ulcer, on dual antiplatelet therapy (eg, aspirin plus a P2Y<sub>12</sub> inhibitor), on concurrent anticoagulant therapy, or with multiple additional risk factors (eg, corticosteroid use, high nonsteroidal anti-inflammatory drug [NSAID] dose, <i>H. pylori</i> infection) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feldman.2021a','lexi-content-ref-Holmes.2019']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feldman.2021a','lexi-content-ref-Holmes.2019'])">Ref</a></span>). For patients on dual antiplatelet therapy, some experts reserve prophylaxis for those with additional risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21060077','lexi-content-ref-28886621']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21060077','lexi-content-ref-28886621'])">Ref</a></span>). Due to a potential drug-drug interaction with clopidogrel, the manufacturer and some experts recommend avoiding concurrent omeprazole use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23425521']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23425521'])">Ref</a></span>); however, some studies have not identified a clinically meaningful interaction (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20925534','lexi-content-ref-20620727']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20925534','lexi-content-ref-20620727'])">Ref</a></span>). If present, <i>H. pylori</i> infection should be treated first (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-19240698','lexi-content-ref-Feldman.2021a']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-19240698','lexi-content-ref-Feldman.2021a'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> 20 mg once daily for the duration of high-risk NSAID use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20925534','lexi-content-ref-9692687','lexi-content-ref-16817839']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20925534','lexi-content-ref-9692687','lexi-content-ref-16817839'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="6a452940-c4b2-4e83-b889-1684a62dda20">Peptic ulcer disease, treatment and secondary prevention</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Peptic ulcer disease, treatment and secondary prevention: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> For patients on NSAIDs (including aspirin), the NSAID should be discontinued, if possible (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Feldman.2019b']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Feldman.2019b'])">Ref</a></span>). If present, <i>H. pylori</i> infection should be treated first; uncomplicated <i>H. pylori–</i>associated ulcers may not need PPI treatment beyond that included in the eradication regimen (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vakil.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vakil.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Uncomplicated ulcer: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 20 to 40 mg once daily. Duration depends on the size, location, and cause of the ulcer and ranges from 4 to 8 weeks. In patients with refractory or recurrent disease, may increase the dose to 20 to 40 mg twice daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vakil.1','lexi-content-ref-Vakil.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vakil.1','lexi-content-ref-Vakil.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Complicated ulcer (perforation, penetration, or gastric outlet obstruction) (off-label use): </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 40 mg twice daily for 4 weeks, followed by 40 mg once daily. Duration depends on the location and etiology of ulcer (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Vakil.2019c']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Vakil.2019c'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Bleeding ulcer: </i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral (preferably following initial use of an IV proton pump inhibitor):</b>
<b>Note</b>: Optimal preendoscopic PPI therapy is uncertain. Some experts suggest initiating high-dose IV PPI with continuous or intermittent dosing in patients with suspected active upper GI bleed prior to endoscopy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Saltzman.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Saltzman.2022'])">Ref</a></span>). Following endoscopy, for patients with high-risk stigmata of recent bleeding (eg, active bleed, visible vessel, adherent clot), a continuous infusion of an IV PPI for at least 72 hours before transitioning to an oral PPI is recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-31634917']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-31634917'])">Ref</a></span>). Patients without high-risk stigmata of recent bleeding can be switched to an oral PPI immediately after endoscopy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Saltzman.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Saltzman.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients with high-risk stigmata of recent bleeding on endoscopy (following IV proton pump inhibitor therapy): 40 mg twice daily for 14 days, followed by 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-Saltzman.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-33929377','lexi-content-ref-31634917','lexi-content-ref-Saltzman.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Patients with no high-risk stigmata of recent bleeding on endoscopy: 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Saltzman.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Saltzman.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Duration: The total duration of treatment depends on size, location, and cause of the ulcer, and ranges from 4 to 12 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31634917','lexi-content-ref-Saltzman.2022','lexi-content-ref-Vakil.2019c','lexi-content-ref-Vakil.3']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31634917','lexi-content-ref-Saltzman.2022','lexi-content-ref-Vakil.2019c','lexi-content-ref-Vakil.3'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Maintenance therapy/secondary prevention (off-label use):</i></p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Note:</b> For select high-risk patients (eg, idiopathic ulcers, frequently recurrent ulcers, need for continued NSAID use).</p>
<p style="text-indent:-2em;margin-left:6em;">
<b>Oral:</b> 20 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-11274623','lexi-content-ref-Feldman.2019b','lexi-content-ref-9494149','lexi-content-ref-9494148']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-11274623','lexi-content-ref-Feldman.2019b','lexi-content-ref-9494149','lexi-content-ref-9494148'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="ddad78db-4422-47a9-8299-1c11f40d1828">Stress ulcer prophylaxis in select critically ill patients</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Stress ulcer prophylaxis in select critically ill patients (off-label use):</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> Used in critically ill patients with risk factors for GI bleeding (eg, coagulopathy, mechanical ventilation for &gt;48 hours, traumatic brain injury, history of GI ulceration or bleeding within past year, extensive burns) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral or via NG tube:</b> 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10690219','lexi-content-ref-9201091']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10690219','lexi-content-ref-9201091'])">Ref</a></span>) <b>or </b>40 mg initially, then another 40 mg dose given 6 to 8 hours later, followed by 40 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-15818102']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-15818102'])">Ref</a></span>). Discontinue prophylaxis once risk factors have resolved (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-34605781','lexi-content-ref-Weinhouse.2022'])">Ref</a></span>).</p></div>
</div>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="a8380a3f-effc-4362-8570-7449b4c89d7a">Zollinger-Ellison syndrome</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Zollinger-Ellison syndrome: </b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 40 mg twice daily; if needed, may titrate upward early in therapy to a maximum of 180 mg/day; once acid output has been controlled, gradual dose reductions are usually possible; reported maintenance dosage range: 10 to 180 mg/day (mean: 60 to 70 mg/day); daily doses &gt;80 mg are usually given in 2 divided doses; continue therapy as long as clinically indicated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Bergsland.2020','lexi-content-ref-2007355','lexi-content-ref-2575060']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Bergsland.2020','lexi-content-ref-2007355','lexi-content-ref-2575060'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>
<b>Discontinuation of therapy:</b></i> In patients who have received continuous therapy for &gt;6 months, some experts gradually taper therapy until discontinuation to avoid worsening or rebound symptoms. There is no single agreed upon discontinuation strategy. If the patient is receiving 40 mg once or twice daily, some experts decrease the dose by 50% every week. For patients receiving twice-daily dosing, the first dose reduction can be achieved by decreasing to once-daily AM dosing. Once patients are on the lowest dose for 1 week, discontinue therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wolfe.2020']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wolfe.2020'])">Ref</a></span>). An alternative strategy is to decrease the dose by 50% over 2 to 4 weeks, then discontinue. If the patient is already on the lowest possible dose, alternate-day therapy may be considered (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-29767318']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-29767318'])">Ref</a></span>). In addition, as-needed therapy with an H<sub>2</sub>RA or an antacid can be used during the taper (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25192903']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25192903'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50991015"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b> Mild to severe impairment: No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-3742939']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-3742939'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Poorly dialyzed: No supplemental dose or dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-4065187']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-4065187'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT:</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration):</b> No dosage adjustment necessary (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50988224"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;display:inline">Mild to severe impairment (Child-Pugh class A, B, or C): 10 mg once daily when used for maintenance of healing of erosive esophagitis. There are no dosage adjustments provided for the other indications. Alternatively, a maximum dose of 20 mg/day regardless of indication, has been recommended (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Losec.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Losec.1'])">Ref</a></span>). In a very small study, omeprazole systemic exposure and half-life increased ~2- and ~3-fold respectively, in patients with mild to severe hepatic impairment.</p></div>
<div class="block arsc drugH1Div" id="F55170020"><span class="drugH1">Adverse Reactions (Significant): Considerations</span>
<div class="collapsible">
<span class="collapsible-title">Cutaneous and systemic lupus erythematosus</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Cutaneous lupus erythematosus</b>, most often subacute cutaneous lupus erythematosus (SCLE), has been reported with use of proton pump inhibitors (PPIs), including omeprazole (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293','lexi-content-ref-23548825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293','lexi-content-ref-23548825'])">Ref</a></span>). SCLE is reversible (resolution ~3 months following discontinuation [range: 4 weeks to 8 months]), and cross-reactivity between PPIs has been reported (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24547721'])">Ref</a></span>). SCLE may present as a widespread skin rash which may include bullous lesions and focal skin necrosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24547721'])">Ref</a></span>). In addition, <b>systemic lupus erythematosus</b> (SLE) secondary to PPIs may occur, although less often as compared to SCLE. Presentation often includes rash, however, arthralgia or cytopenia may also occur.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic. SCLE is typically associated with positive antinuclear antibodies (ANA), anti-Ro/SSA and anti-La/SSB antibodies (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23548825']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23548825'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied.</p>
<p style="text-indent:-2em;margin-left:6em;">Cutaneous lupus erythematosus: ~8 months following treatment initiation (range: 3 days to 3.5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-18176768','lexi-content-ref-32639541','lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-18176768','lexi-content-ref-32639541','lexi-content-ref-24547721'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Systemic lupus erythematosus: According to the manufacturer, may occur within days to years after initiating treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history or family history of SCLE, especially secondary to PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293','lexi-content-ref-24547721']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293','lexi-content-ref-24547721'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for SCLE (eg, female of childbearing age, periods of female hormone changes, prior history of drug allergies, sun-reactive skin, exposure to UV radiation) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27398293']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27398293'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Enteric infections</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of proton pump inhibitors (PPIs), including omeprazole, may increase risk of enteric infections in adult and pediatric patients, including gastroenteritis and <b>
<i>Clostridioides difficile-</i>associated diarrhea </b>(CDAD); however data are conflicting, especially with regard to CDAD (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16651285','lexi-content-ref-31378636','lexi-content-ref-31152740','lexi-content-ref-25112692','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-20047577','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16651285','lexi-content-ref-31378636','lexi-content-ref-31152740','lexi-content-ref-25112692','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-20047577','lexi-content-ref-28054368'])">Ref</a></span>). <b>Diarrhea</b>, which may be a result of enteric infection, is the most common adverse effect secondary to long-term PPI use and often results in treatment discontinuation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243'])">Ref</a></span>). Consider CDAD diagnosis in patients with persistent diarrhea that does not improve, especially in hospitalized patients.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28054368'])">Ref</a></span>); related to the pharmacologic action. The increase in gastric pH secondary to PPI administration leads to changes in intestinal microbial environment which may allow for intestinal germination and growth of <i>C. difficile </i>spores as well as colonization by other bacteria responsible for enteric infections (eg, <i>Salmonella</i>, <i>Campylobacter</i>, <i>Shigella</i>, norovirus) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584','lexi-content-ref-28325163']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584','lexi-content-ref-28325163'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; hospitalized patients receiving high doses may experience CDAD within days of treatment initiation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31187275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31187275'])">Ref</a></span>) whereas others develop gastroenteritis with long-term therapy in the community setting (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243','lexi-content-ref-28054368'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (eg, daily or more frequently than daily use) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-28054368']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20458086','lexi-content-ref-31187275','lexi-content-ref-28325163','lexi-content-ref-28054368'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Hospitalized patients (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28842261','lexi-content-ref-31187275']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28842261','lexi-content-ref-31187275'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Infants and children with defective immune systems or indwelling catheters (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25752807']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25752807'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fractures</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Use of proton pump inhibitors (PPIs), including omeprazole, may increase the risk of <b>bone</b>
<b>fracture</b> in children, young adults, and older adults, including osteoporosis-related fractures (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-25986385','lexi-content-ref-31175146','lexi-content-ref-30237993','lexi-content-ref-18695179','lexi-content-ref-32176276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-25986385','lexi-content-ref-31175146','lexi-content-ref-30237993','lexi-content-ref-18695179','lexi-content-ref-32176276'])">Ref</a></span>). However, data regarding the impact of PPIs on fractures, as well as bone mineral density (BMD), are inconclusive and some have concluded that any association with fracture may be related to other independent risk factors (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-20458083','lexi-content-ref-30237993','lexi-content-ref-23455632','lexi-content-ref-31060319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-20458083','lexi-content-ref-30237993','lexi-content-ref-23455632','lexi-content-ref-31060319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose-related; related to the pharmacologic action (hypergastrinemia and hypochlorhydria). Hypergastrinemia causes secondary hyperparathyroidism which can increase bone resorption and subsequent decreased BMD. Hypochlorhydria results in decreased absorption of calcium, magnesium, and vitamin B<sub>12</sub>. Impaired calcium absorption may cause secondary hyperparathyroidism and decreased BMD. Decreased vitamin B<sub>12</sub> absorption may decrease osteoblastic activity leading to decreased BMD, as well as decreased collagen cross-linking leading to weakened bone structure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31060319']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31060319'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (≥1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24507954','lexi-content-ref-18695179']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24507954','lexi-content-ref-18695179'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for fractures and/or osteoporosis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-20353792','lexi-content-ref-32058466','lexi-content-ref-30262672']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-20353792','lexi-content-ref-32058466','lexi-content-ref-30262672'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (eg, ≥1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24507954','lexi-content-ref-18695179','lexi-content-ref-32176276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24507954','lexi-content-ref-18695179','lexi-content-ref-32176276'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (≥1.5 doses per day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-20353792']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-20353792'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric: Initiation of therapy at age &lt;1 year or ≥6 years (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31175146','lexi-content-ref-32176276']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31175146','lexi-content-ref-32176276'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Pediatric: Concurrent use of PPI plus H<sub>2</sub> blocker (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31175146']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31175146'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Fundic gland polyps</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of proton pump inhibitors (PPIs), including omeprazole, has been associated with the development of reversible <b>gastric polyp </b>(fundic gland) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515','lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515','lexi-content-ref-32718584'])">Ref</a></span>). Most PPI users who developed fundic gland polyps were asymptomatic. Symptomatic patients may report nausea, vomiting, or abdominal pain. GI bleeding and/or anemia may occur with ulcerated polyp. Clinicians should note that <i>Helicobacter pylori </i>infection may be protective against fundic gland polyps as bacterial proteases help glandular outflow by breaking down blockages (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; long-term use of PPIs is associated with an increase in the prevalence of parietal cell protrusions which cause outflow blockage of the isthmus and subsequent formation of fundic gland cysts. As therapy continues, fundic gland cysts may enlarge and develop into fundic gland polyps (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-21365243'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (&gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients with familial adenomatous polyposis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of treatment (&gt;1 year and especially ≥5 years) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17059515']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17059515'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypersensitivity reactions (immediate and delayed)</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Immediate hypersensitivity reactions secondary to proton pump inhibitors (PPIs) are rare and range from <b>urticaria</b> and <b>angioedema</b> to <b>anaphylaxis </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-22697020','lexi-content-ref-24267357','lexi-content-ref-30675130','lexi-content-ref-21626263','lexi-content-ref-19274931']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-22697020','lexi-content-ref-24267357','lexi-content-ref-30675130','lexi-content-ref-21626263','lexi-content-ref-19274931'])">Ref</a></span>). Delayed hypersensitivity reactions include <b>maculopapular rash</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23134998']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23134998'])">Ref</a></span>) as well as rare severe cutaneous adverse reactions (SCARs) such as <b>acute generalized exanthematous pustulosis</b>, <b>drug reaction with eosinophilia and systemic symptoms</b>, <b>Stevens-Johnson syndrome</b>, and <b>toxic epidermal necrolysis</b> (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24751668','lexi-content-ref-27134114','lexi-content-ref-28658503','lexi-content-ref-30051945','lexi-content-ref-19659985']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24751668','lexi-content-ref-27134114','lexi-content-ref-28658503','lexi-content-ref-30051945','lexi-content-ref-19659985'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; immunologic.</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions (eg, anaphylaxis, urticaria): IgE-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24267357']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24267357'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions (including maculopapular rash and SCARs): T-cell-mediated (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-21470217']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-21470217'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">Immediate hypersensitivity reactions: Rapid; occurs within 1 hour of administration but may occur up to 6 hours after exposure (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-24267357','lexi-content-ref-24834779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-24267357','lexi-content-ref-24834779'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:6em;">Delayed hypersensitivity reactions<i>:</i></p>
<p style="text-indent:-2em;margin-left:8em;">Maculopapular reactions: Intermediate; generally occurs 7 to 10 days after initiation, but may occur up to 1 month following initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28658503']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28658503'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:8em;">Other reactions (including SCARs): Varied; occurs after 7 to 14 days up to 3 months following initiation of therapy (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30558872','lexi-content-ref-24751668','lexi-content-ref-26120552','lexi-content-ref-28658503','lexi-content-ref-NICE.2014']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30558872','lexi-content-ref-24751668','lexi-content-ref-26120552','lexi-content-ref-28658503','lexi-content-ref-NICE.2014'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Prior history of hypersensitivity reaction to PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16440530']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16440530'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactivity has been noted with PPIs, although cross-reactivity patterns have been variable (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-30058396','lexi-content-ref-24267357','lexi-content-ref-24834779']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-30058396','lexi-content-ref-24267357','lexi-content-ref-24834779'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Hypomagnesemia</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of proton pump inhibitors (PPIs), including omeprazole, has resulted in reversible <b>hypomagnesemia </b>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-26108134','lexi-content-ref-18221401','lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-26108134','lexi-content-ref-18221401','lexi-content-ref-32718584'])">Ref</a></span>). Symptoms may be severe (eg, tetany, cardiac arrhythmias, cerebellar syndrome, seizures) and resistant to treatment with supplementation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-28401712','lexi-content-ref-18221401','lexi-content-ref-22800870','lexi-content-ref-20378675']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-28401712','lexi-content-ref-18221401','lexi-content-ref-22800870','lexi-content-ref-20378675'])">Ref</a></span>). May require discontinuation of PPI in addition to magnesium supplementation in ~25% of patients. Following discontinuation, magnesium normalizes after ~1 week (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>). Hypomagnesemia may recur if PPI therapy is restarted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011','lexi-content-ref-21930865']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011','lexi-content-ref-21930865'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Time-related; the specific mechanism is unknown; however, long-term use of PPIs may be associated with changes in intestinal absorption of magnesium (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011','lexi-content-ref-32718584']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011','lexi-content-ref-32718584'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed; hypomagnesemia occurs most often after 1 year of therapy but may occur as early as 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>). In patients with prior PPI-induced hypomagnesemia, re-initiation may result in recurrence within 2 weeks (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (≥3 months and especially &gt;1 year) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Concurrent use of other drugs that cause hypomagnesemia (eg, loop diuretics, thiazide diuretics) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-FDA.2011'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Patients who have undergone kidney transplantation (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-31817776','lexi-content-ref-FDA.2011']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-31817776','lexi-content-ref-FDA.2011'])">Ref</a></span>)</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Interstitial nephritis</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Acute interstitial nephritis</b> (AIN) may occur rarely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17635502','lexi-content-ref-25323274','lexi-content-ref-23960351','lexi-content-ref-32128193']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17635502','lexi-content-ref-25323274','lexi-content-ref-23960351','lexi-content-ref-32128193'])">Ref</a></span>), with renal biopsy showing diffuse interstitial infiltrate and tubulitis (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24629073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24629073'])">Ref</a></span>). Patients generally achieve complete or partial recovery by 6 months following treatment of AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24927897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24927897'])">Ref</a></span>). Signs of systemic hypersensitivity (fever, rash, eosinophilia) often seen in other cases of drug-induced AIN are <b>not</b> typically observed in proton pump inhibitor (PPI)-induced AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611','lexi-content-ref-24927897']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611','lexi-content-ref-24927897'])">Ref</a></span>). Clinicians should note that there appears to be <b>no</b> correlation between duration of exposure to PPI and duration or severity of acute kidney failure after resolution of AIN (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Non-dose-related; unknown although may be immunologic (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24629073']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24629073'])">Ref</a></span>) or idiosyncratic, with direct toxic effect of omeprazole on tubular cells (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32092686']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32092686'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Varied; usually occurs within 3 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-16630752','lexi-content-ref-17635502','lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-16630752','lexi-content-ref-17635502','lexi-content-ref-23109611'])">Ref</a></span>) although has been reported to occur up to 10 months (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24629073','lexi-content-ref-21143456']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24629073','lexi-content-ref-21143456'])">Ref</a></span>). Upon reexposure symptoms often present more rapidly, often within 12 hours (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-17635502']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-17635502'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Older adults; although this may be due to increased use of PPIs (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23109611']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23109611'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Cross-reactions among PPIs in patients who developed AIN is not known</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Vitamin B12 deficiency</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:2em;">Long-term use of acid suppressive therapies, including omeprazole, may result in reversible <b>vitamin B<sub>12</sub> deficiency</b>; however, data regarding the clinical significance of these changes and causality are conflicted (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038','lexi-content-ref-29610598','lexi-content-ref-30792587']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038','lexi-content-ref-29610598','lexi-content-ref-30792587'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Mechanism</i>: Dose- and time-related; acid suppressive therapies interfere with acid-activated proteolytic digestion of dietary protein-bound vitamin B<sub>12</sub> in the stomach, thereby resulting in malabsorption of vitamin B<sub>12 </sub>(<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23010681','lexi-content-ref-24327038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23010681','lexi-content-ref-24327038'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Onset</i>: Delayed (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Risk factors</i>:</p>
<p style="text-indent:-2em;margin-left:6em;">• Duration of therapy (≥2 to 3 years); the association between ≥2 years of proton pump inhibitor (PPI) use and vitamin B<sub>12</sub> deficiency was stronger among people &lt;30 years of age and in females (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• High doses of PPIs (≥1.5 pills per day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-24327038','lexi-content-ref-9626024']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-24327038','lexi-content-ref-9626024'])">Ref</a></span>)</p>
<p style="text-indent:-2em;margin-left:6em;">• Presence of risk factors for vitamin B<sub>12</sub> deficiency (eg, malnourished patients, vegan diet) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32718584','lexi-content-ref-21365243']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32718584','lexi-content-ref-21365243'])">Ref</a></span>)</p></div>
</div>
</div>
<div class="block adr drugH1Div" id="F203524"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Respiratory: Respiratory system disorder (infants: 42%; children 1 to &lt;2 years: 75%; children ≥2 years and adolescents: 19%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Skin rash (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal pain (5%), constipation (2%), diarrhea (4%), flatulence (3%), nausea (4%), vomiting (3%)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Asthenia (1%), dizziness (2%), headache (7%)</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Back pain (1%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Cough (1%), upper respiratory infection (2%)</p>
<p style="text-indent:-2em;margin-left:2em;">Postmarketing:</p>
<p style="text-indent:-2em;margin-left:4em;">Cardiovascular: Acute coronary syndrome (Kounis syndrome) (Gázquez 2010), angina pectoris, bradycardia, chest pain, increased blood pressure, palpitations, peripheral edema (Brunner 2001), tachycardia</p>
<p style="text-indent:-2em;margin-left:4em;">Dermatologic: Acute generalized exanthematous pustulosis, alopecia (Borum 1997), cutaneous lupus erythematosus (Toms-Whittle 2011), dermatitis (Jurakić Tončić 2019, Rebuck 1998), hyperhidrosis (Mamun 1999), hypertrichosis (Elosua-González 2018), maculopapular rash (Chularojanamontri 2012), pruritus (Bose 2013), skin photosensitivity, Stevens-Johnson syndrome (Lin 2018; Van Tendeloo 2020), toxic epidermal necrolysis (Lin 2018; Thakor 2009), urticaria (Bose 2013; Bowlby 1994), xeroderma</p>
<p style="text-indent:-2em;margin-left:4em;">Endocrine &amp; metabolic: Galactorrhea not associated with childbirth (Dorji 2022), gynecomastia (Convens 1991), hypocalcemia (Shabajee 2008), hypoglycemia, hypokalemia (Maeda 2011), hypomagnesemia (Shabajee 2008), hyponatremia (Shiba 1996), vitamin B<sub>12</sub> deficiency (Lam 2013), weight gain</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Abdominal swelling, anorexia, benign polyp of the stomach (Miyamoto 2017), <i>Clostridioides difficile</i>-associated diarrhea (Li 2017), colitis (microscopic) (Wilcox 2009), dysgeusia (Markitiziu 1996), esophageal candidiasis (Larner 1992, Sood 1995), fecal discoloration, gastric polyp (fundic gland; with chronic use [&gt;1 year] ) (Jalving 2006), gastroenteritis (Canani 2006, Houben 2018, Wei 2017), irritable bowel syndrome, pancreatitis (Youssef 2005), stomatitis, tongue mucosa atrophy, xerostomia (Teare 1995)</p>
<p style="text-indent:-2em;margin-left:4em;">Genitourinary: Erectile dysfunction, glycosuria, hematuria (Myers 2001), microscopic pyuria (Myers 2001), proteinuria (Myers 2001), testicular pain, urinary frequency, urinary tract infection</p>
<p style="text-indent:-2em;margin-left:4em;">Hematologic &amp; oncologic: Agranulocytosis (Ottervanger 1995), anemia (including iron deficiency anemia) (Imai 2018), hemolytic anemia (Marks 1991), leukocytosis, leukopenia (Odou 1999), neutropenia (Gouraud 2010, Holt 1999), pancytopenia, petechia, thrombocytopenia (Kallam 2015)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Cholestatic hepatitis, hepatic encephalopathy, hepatic failure (Jochem 1992), hepatic necrosis, hepatocellular hepatitis, hepatotoxicity (idiosyncratic) (Chalasani 2021)</p>
<p style="text-indent:-2em;margin-left:4em;">Hypersensitivity: Anaphylactic shock (González-Rubio 2017), angioedema (Bose 2013; Bowlby 1994), drug reaction with eosinophilia and systemic symptoms (Lin 2018)</p>
<p style="text-indent:-2em;margin-left:4em;">Nervous system: Abnormal dreams, aggressive behavior, agitation, anxiety, apathy, confusion, dementia (Gomm 2016), depression, drowsiness, fatigue, hallucination (Sebastián Domingo 2018), insomnia, myasthenia, nervousness, pain, paresthesia, sleep disturbance, tremor, vertigo</p>
<p style="text-indent:-2em;margin-left:4em;">Neuromuscular &amp; skeletal: Arthralgia (Beutler 1994), bone fracture (Nassar 2018), lower leg pain, muscle cramps, myalgia, systemic lupus erythematosus</p>
<p style="text-indent:-2em;margin-left:4em;">Ophthalmic: Anterior ischemic optic neuropathy (Schonhofer 1997), blurred vision, diplopia, dry eye syndrome, eye irritation, optic atrophy, optic neuritis</p>
<p style="text-indent:-2em;margin-left:4em;">Otic: Tinnitus</p>
<p style="text-indent:-2em;margin-left:4em;">Renal: Acute interstitial nephritis (Klassen 2013; Yip 1997), kidney disease (chronic; Lazarus 2016)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Bronchospasm, epistaxis, pharyngitis, pneumonia (community-acquired; in pediatric patients 4 to 36 months of age) (Canani 2006)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Fever</p></div>
<div class="block coi drugH1Div" id="F203539"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity (eg, anaphylaxis, anaphylactic shock, angioedema, bronchospasm, acute tubulointerstitial nephritis, urticaria) to omeprazole, other substituted benzimidazole proton pump inhibitors, or any component of the formulation; concomitant use with products that contain rilpivirine.</p>
<p style="text-indent:-2em;margin-left:2em;">Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p>
<p style="text-indent:-2em;margin-left:2em;">OTC labeling: When used for self-medication (OTC), do not use if hypersensitive to omeprazole or any component of the formulation; trouble or pain when swallowing food; vomiting with blood, or bloody or black stools; heartburn with lightheadedness, dizziness, or sweating; chest pain or shoulder pain with shortness of breath, sweating, pain spreading to arms, neck or shoulders, or lightheadedness; frequent chest pain.</p></div>
<div class="block war drugH1Div" id="F203521"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Carcinoma: In long-term (2-year) studies in rats, omeprazole produced a dose-related increase in gastric carcinoid tumors. While available endoscopic evaluations and histologic examinations of biopsy specimens from human stomachs have not detected a risk from short-term exposure to omeprazole, further human data on the effect of sustained hypochlorhydria and hypergastrinemia are needed to rule out the possibility of an increased risk for the development of tumors in humans receiving long-term therapy.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Gastric malignancy: Relief of symptoms does not preclude the presence of a gastric malignancy.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: In patients with hepatic impairment (Child-Pugh class A, B, or C) exposure to omeprazole is increased; dosage reduction is recommended.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concurrent drug therapy issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Clopidogrel: PPIs may diminish the therapeutic effect of clopidogrel, thought to be due to reduced formation of the active metabolite of clopidogrel. The manufacturer of clopidogrel recommends either avoidance of both omeprazole (even when scheduled 12 hours apart) and esomeprazole or use of a PPI with comparatively less effect on the active metabolite of clopidogrel (eg, pantoprazole). In contrast to these warnings, others have recommended the continued use of PPIs, regardless of the degree of inhibition, in patients with a history of GI bleeding or multiple risk factors for GI bleeding who are also receiving clopidogrel since no evidence has established clinically meaningful differences in outcome; however, a clinically significant interaction cannot be excluded in those who are poor metabolizers of clopidogrel (Abraham, 2010; Levine, 2011).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Asian ethnicity: Bioavailability is increased in patients of Asian descent; dosage reduction is recommended for maintenance healing of erosive esophagitis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Bioavailability may be increased in older adults.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Dosage form specific issues:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Benzyl alcohol and derivatives: Some dosage forms may contain benzyl alcohol; large amounts of benzyl alcohol (≥99 mg/kg/day) have been associated with a potentially fatal toxicity (“gasping syndrome”) in neonates; the “gasping syndrome” consists of metabolic acidosis, respiratory distress, gasping respirations, CNS dysfunction (including convulsions, intracranial hemorrhage), hypotension, and cardiovascular collapse (AAP ["Inactive" 1997]; CDC 1982); some data suggests that benzoate displaces bilirubin from protein binding sites (Ahlfors 2001); avoid or use dosage forms containing benzyl alcohol with caution in neonates. See manufacturer's labeling.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: <i>Helicobacter pylori</i> eradication: Short-term combination therapy (≤7 days) has been associated with a higher incidence of treatment failure. The American College of Gastroenterology recommends 10 to 14 days of therapy (triple or quadruple) for eradication of <i>H. pylori</i> (Chey 2017).</p>
<p style="text-indent:-2em;margin-left:4em;">• Laboratory test interference: Serum chromogranin A (CgA) levels increase secondary to drug-induced decreases in gastric acid; may cause false-positive results in diagnostic investigations for neuroendocrine tumors. Temporarily stop omeprazole treatment at least 14 days before CgA test; if initial CgA levels are high, repeat test to confirm. Use same commercial laboratory for testing to prevent variable results.</p>
<p style="text-indent:-2em;margin-left:4em;">• Self-medication (OTC use): When used for self-medication (OTC), notify health care provider before use if any of the following are present: heartburn for &gt;3 months; frequent wheezing, particularly with heartburn; unexplained weight loss; nausea or vomiting; or stomach pain. Discontinue use and notify health care provider if heartburn continues or worsens; diarrhea occurs; if &gt;14 days of therapy is needed; or if &gt;1 course of therapy is needed every 4 months.</p></div>
<div class="block add-pediatric-warn-info drugH1Div" id="F53406705"><span class="drugH1">Warnings: Additional Pediatric Considerations</span>
<p style="text-indent:0em;display:inline">Routine use in preterm infants is not recommended (AAP [Eichenwald 2018]).</p></div>
<div class="block dosfc drugH1Div" id="F45040042"><span class="drugH1">Dosage Forms Considerations</span>
<p style="text-indent:0em;display:inline">First-Omeprazole oral suspension is a compounding kit. Refer to manufacturer's labeling for compounding instructions.</p></div>
<div class="block foc drugH1Div" id="F203531"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Packet, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PriLOSEC: 2.5 mg (30 ea); 10 mg (30 ea)</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg, 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Acid Reducer: 20 mg [contains corn starch]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PriLOSEC OTC: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">PriLOSEC OTC: 20 mg [contains fd&amp;c blue #2 (indigo carm) aluminum lake, fd&amp;c red #40(allura red ac)aluminum lake, saccharin sodium; wild berry flavor]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg</p></div>
<div class="block geq drugH1Div" id="F203517"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">May be product dependent</p></div>
<div class="block fee drugH1Div" id="F203541"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Omeprazole Magnesium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20.6 (20 Base) mg (per each): $0.59 - $0.77</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Capsule, delayed release</b> (Omeprazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $3.01 - $3.99</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $3.37 - $4.45</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">40 mg (per each): $0.33 - $7.40</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Pack</b> (PriLOSEC Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2.5 mg (per each): $16.61</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">10 mg (per each): $16.61</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Omeprazole Magnesium Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.60 - $0.81</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (Omeprazole Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.62 - $0.94</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablet, EC</b> (PriLOSEC OTC Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">20 mg (per each): $0.86</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867758"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Capsule Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Losec: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg, 20 mg, 40 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 10 mg</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet Delayed Release, Oral, as magnesium [strength expressed as base]: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Losec: 20 mg [DSC]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Losec Mups: 20 mg</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 20 mg</p></div>
<div class="block exp drugH1Div" id="F203537"><span class="drugH1">Extemporaneous Preparations</span>
<p style="text-indent:0em;display:inline">
<b>Note:</b> A more palatable omeprazole (2 mg/mL) suspension is commercially available as a compounding kit (First-Omeprazole).</p>
<p style="text-indent:0em;margin-top:2em;">
<b>2 mg/mL Oral Solution</b></p>
<p style="text-indent:0em;margin-top:2em;">A 2 mg/mL oral omeprazole solution (Simplified Omeprazole Solution) may be made with five omeprazole 20 mg delayed release capsules and 50 mL sodium bicarbonate 8.4%. Empty capsules into beaker. Add sodium bicarbonate solution. Gently stir (about 15 minutes) until a white suspension forms. Transfer to amber-colored syringe or bottle. Stable for 14 days at room temperature or for 30 days refrigerated.</p>
<div class="reference">DiGiacinto JL, Olsen KM, Bergman KL, et al, “Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes,” <i>Ann Pharmacother</i>, 2000, 34(5):600-5.<span class="pubmed-id">10852086</span></div>
<div class="reference">Quercia R, Fan C, Liu X, et al, “Stability of Omeprazole in an Extemporaneously Prepared Oral Liquid,” <i>Am J Health Syst Pharm</i>, 1997, 54(16):1833-6.<span class="pubmed-id">9269520</span></div>
<div class="reference">Sharma V, “Comparison of 24-hour Intragastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole,” <i>Am J Health Syst Pharm</i>, 1999, 56(23 Suppl 4):18-21.<span class="pubmed-id">10597120</span></div>
</div>
<div class="block admp drugH1Div" id="F52613469"><span class="drugH1">Administration: Pediatric</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: Should be taken before meals; best if taken 30 minutes before a meal (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23629618']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23629618'])">Ref</a></span>); may be administered with antacids.</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Should be swallowed whole; do not chew or crush. Delayed-release capsule may be opened and contents added to 1 tablespoon of applesauce; use immediately after adding to applesauce; do not chew or crush. Follow with a cool glass of water. Applesauce should not be heated; do not store mixture for future use.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Empty the contents of the 2.5 mg packet into 5 mL of water or 10 mg packet into 15 mL of water and stir; allow the suspension to sit for 2 to 3 minutes to thicken; stir and administer within 30 minutes. If any material remains after administration, add more water, stir, and administer immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Should be swallowed whole; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:2em;">Nasogastric or gastric tube administration:</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: The manufacturer of Prilosec does not give recommendations for extemporaneous preparation of omeprazole capsules for NG/OG administration. Consider using the packets for oral suspension. If packets are unavailable, methods of preparation of capsules for NG/OG administration have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8995942','lexi-content-ref-8917027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8995942','lexi-content-ref-8917027'])">Ref</a></span>). An extemporaneously prepared suspension with extended stability may also be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10852086','lexi-content-ref-9269520','lexi-content-ref-10597120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10852086','lexi-content-ref-9269520','lexi-content-ref-10597120'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Add 5 mL of water to a catheter-tipped syringe and then add the contents of a 2.5 mg packet (or 15 mL of water for the 10 mg packet), shake the suspension well, and leave to thicken for 2 to 3 minutes. Shake the syringe and administer through nasogastric or gastric tube (French size 6 or greater) within 30 minutes of reconstitution. Refill syringe with an equal amount (5 mL or 15 mL) of water, shake, and flush remaining contents through NG or gastric tube.</p></div>
<div class="block adm drugH1Div" id="F203535"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:-2em;margin-left:2em;">Oral: For most indications, administer 30 to 60 minutes before a meal; best if taken before breakfast (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381'])">Ref</a></span>). If administering twice daily, first dose should be administered before breakfast and the second dose before dinner (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-23419381','lexi-content-ref-21126704']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-23419381','lexi-content-ref-21126704'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">Capsule: Swallow whole; do not chew or crush. Capsule may be opened and contents mixed with 1 tablespoon of applesauce (soft enough to swallow without chewing). Swallow immediately with a glass of cool water; mixture should not be chewed, crushed, warmed, or saved for future use.</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension: Following reconstitution, the suspension should be left to thicken for 2 to 3 minutes and administered within 30 minutes. If any material remains after administration, add more water, stir, and administer immediately.</p>
<p style="text-indent:-2em;margin-left:4em;">Tablet: Swallow whole with a glass of water before morning meal; do not crush or chew.</p>
<p style="text-indent:-2em;margin-left:6em;">Bariatric surgery: Tablet, delayed release: Some institutions may have specific protocols that conflict with these recommendations; refer to institutional protocols as appropriate. Oral capsule and suspension formulations are available. If safety and efficacy can be effectively monitored, no change in formulation or administration is required after bariatric surgery; however, for patients with refractory acid reflux, esophagitis, Barrett esophagus, or ulcer, it is advised to open contents of the capsule and mix with 1 tablespoon of applesauce. Swallow immediately without chewing, crushing, warming, or saving for future use. If there is inadequate response to omeprazole consider escalation of therapy to twice a day, or conversion to food independent proton pump inhibitor (omeprazole/sodium bicarbonate or dexlansoprazole).</p>
<p style="text-indent:-2em;margin-left:2em;">NG/Gastric tube:</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension (using packets): Add 5 mL of water to a catheter tipped syringe and then add contents of a 2.5 mg packet (or 15 mL of water for the 10 mg packet). Immediately shake syringe and leave to thicken for 2 to 3 minutes; shake syringe again and within 30 minutes administer via NG or gastric tube (French size 6 or larger). Refill syringe with an equal amount of water, shake, and flush remaining contents through NG or gastric tube</p>
<p style="text-indent:-2em;margin-left:4em;">Oral suspension (using capsules): The manufacturer of Prilosec does not give recommendations for extemporaneous preparation of omeprazole capsules for NG/OG administration. Consider using the packets for oral suspension. If packets are unavailable, methods of preparation of capsules for NG/OG administration have been described (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8995942','lexi-content-ref-8917027']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8995942','lexi-content-ref-8917027'])">Ref</a></span>). An extemporaneously prepared suspension with extended stability may also be used (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10852086','lexi-content-ref-9269520','lexi-content-ref-10597120']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10852086','lexi-content-ref-9269520','lexi-content-ref-10597120'])">Ref</a></span>).</p></div>
<div class="block sts drugH1Div" id="F203552"><span class="drugH1">Storage/Stability</span>
<p style="text-indent:-2em;margin-left:2em;">Capsules, tablets: Store at 15°C to 30°C (59°F to 86°F). Protect from light and moisture.</p>
<p style="text-indent:-2em;margin-left:2em;">Granules for oral suspension: Store at 25°C (77°F); excursions permitted to 15°C to 30°C (59°F to 86°F).</p>
<p style="text-indent:-2em;margin-left:2em;">Powder for suspension (compounding kits): Refer to manufacturer's labeling. </p>
<p style="text-indent:-2em;margin-left:2em;">OTC capsules: Store at 20°C to 25°C (68°F to 77°F); protect from moisture. </p></div>
<div class="block meg drugH1Div" id="F15241703"><span class="drugH1">Medication Guide and/or Vaccine Information Statement (VIS)</span>
<p style="text-indent:0em;display:inline">An FDA-approved patient medication guide, which is available with the product information and as follows, must be dispensed with this medication:</p>
<p style="text-indent:-2em;margin-left:4em;">Prilosec capsules: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2018%2F022056s022lbl.pdf%23page%3D35&amp;token=GH57MjH1lx0bUp10CA2EgwS5YYM57eCImt5qTbxQcs7t4PTUqdIE%2B38ue54l18HcYY1U18EDui9wibCY37JXdWnxlRH2Le%2Be1Q8m8Ifcfa86IfZmSO%2BcKWNASWNCLCez&amp;TOPIC_ID=12658" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/022056s022lbl.pdf#page=35</a></p>
<p style="text-indent:-2em;margin-left:4em;">Prilosec granules for oral suspension: <a href="/external-redirect?target_url=https%3A%2F%2Fwww.accessdata.fda.gov%2Fdrugsatfda_docs%2Flabel%2F2023%2F022056s026lbl.pdf%23page%3D34&amp;token=unAT410PATSZAc5e7LbUtPQs9td8vcFHCOq1wiq0Q8hl3kAC7QjL3KN78P%2Bf%2BH457w1x9iyhaTnAvHhwkZihztaysEapvLBqx4jDekKqS2IuCGtr%2FlXncdmjfwJQjp4i&amp;TOPIC_ID=12658" target="_blank">https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/022056s026lbl.pdf#page=34</a></p></div>
<div class="block usep drugH1Div" id="F53568092"><span class="drugH1">Use</span>
<p style="text-indent:0em;display:inline">Short-term treatment (up to 6 weeks) of erosive esophagitis due to acid-mediated gastroesophageal reflux disease (GERD) (FDA approved in ages 1 month to &lt;1 year); short-term treatment (4 to 8 weeks) of erosive esophagitis due to acid-mediated GERD diagnosed by endoscopy (FDA approved in ages ≥1 year and adults); maintenance of healing of erosive esophagitis due to acid-mediated GERD (FDA approved in ages ≥1 year and adults); treatment of heartburn and other symptoms associated with GERD (FDA approved in ages ≥1 year and adults); short-term treatment (4 to 8 weeks) of active duodenal ulcers and active benign gastric ulcers (FDA approved in adults); treatment (in combination with clarithromycin ± amoxicillin) for <i>Helicobacter pylori</i> eradication in patients with duodenal ulcer disease (active or up to 1-year history) to reduce recurrence of duodenal ulcer (FDA approved in adults); long-term treatment of pathological hypersecretory conditions (eg, Zollinger-Ellison syndrome, multiple endocrine adenomas, systemic mastocytosis) (FDA approved in adults); relief of frequent (≥2 days per week) heartburn (OTC products: FDA approved in adults)</p></div>
<div class="block mst drugH1Div" id="F203615"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Omeprazole may be confused with ARIPiprazole, esomeprazole, fomepizole</p>
<p style="text-indent:-2em;margin-left:4em;">PriLOSEC may be confused with Plendil, Prevacid, predniSONE, prilocaine, Prinivil, Pristiq, Proventil, PROzac</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Omeprazole is identified in the Beers Criteria as a potentially inappropriate medication to be avoided (as scheduled use for &gt;8 weeks) in patients 65 years and older due to its risk of <i>C. difficile</i> infection, pneumonia, GI malignancies, and bone loss/fractures unless given for high-risk patients (eg, oral corticosteroid or chronic NSAID use), patients with erosive esophagitis, Barrett’s esophagitis, a pathological hypersecretory condition, or if the patient has demonstrated a need for maintenance therapy (eg, failure of drug discontinuation trial or failure of H<sub>2</sub> blockers) (Beers Criteria [AGS 2023]).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Losec [multiple international markets] may be confused with Lasix brand name for furosemide [US, Canada, and multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Medral [Mexico] may be confused with Medrol brand name for methylprednisolone [US., Canada, and multiple international markets]</p>
<p style="text-indent:-2em;margin-left:4em;">Norpramin: Brand name for omeprazole [Spain], but also the brand name for desipramine [US, Canada] and enalapril/hydrochlorothiazide [Portugal]</p>
<p style="text-indent:-2em;margin-left:4em;">Protonix: Brand name for omeprazole [Philippines] but also the brand name for pantoprazole [US]</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F203601"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2A6 (minor), CYP2C19 (major), CYP2C9 (minor), CYP2D6 (minor), CYP3A4 (minor); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential; <b>Inhibits</b> CYP2C19 (weak), OAT1/3</p></div>
<div class="block dri drugH1Div" id="F203526"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Acalabrutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Acalabrutinib. This interaction is only applicable to acalabrutinib capsules. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Amphetamine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Atazanavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Atazanavir.  Management: Avoid use in treatment-experienced patients. In treatment-naive patients, administer boosted atazanavir 12 hours after the PPI and the PPI dose should not exceed the equivalent of 20 mg omeprazole. Monitor for reduced atazanavir efficacy.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Belumosudil: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Belumosudil.  Management: Increase the dose of belumosudil to 200 mg twice daily when coadministered with inhibitors of the proton pump (PPIs and PCABs).<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bisphosphonate Derivatives: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Bisphosphonate Derivatives. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bosutinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Bosutinib.  Management: Consider alternatives to proton pump inhibitors and potassium-competitive acid blockers, such as short-acting antacids or histamine-2 receptor antagonists. Administer alternative agents more than 2 hours before or after bosutinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Capecitabine: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Capecitabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CarBAMazepine: May decrease the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of CarBAMazepine.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefditoren: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefditoren. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefpodoxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Cefpodoxime. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cefuroxime: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Cefuroxime. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cilostazol: Omeprazole may increase serum concentrations of the active metabolite(s) of Cilostazol. Omeprazole may increase the serum concentration of Cilostazol.  Management: Reduce the cilostazol dose to 50 mg twice daily in patients who are also receiving omeprazole. Monitor clinical response to cilostazol closely.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Citalopram: Omeprazole may increase the serum concentration of Citalopram.  Management: Limit citalopram dose to a maximum of 20 mg/day if used with omeprazole. Monitor for evidence of citalopram toxicity (eg, serotonin syndrome, QT prolongation) in patients receiving this combination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloBAZam: CYP2C19 Inhibitors (Weak) may increase serum concentrations of the active metabolite(s) of CloBAZam. CYP2C19 Inhibitors (Weak) may increase the serum concentration of CloBAZam. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clofarabine: OAT1/3 Inhibitors may increase the serum concentration of Clofarabine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clopidogrel: Omeprazole may diminish the antiplatelet effect of Clopidogrel. Omeprazole may decrease serum concentrations of the active metabolite(s) of Clopidogrel. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CloZAPine: Omeprazole may decrease the serum concentration of CloZAPine. Omeprazole may increase the serum concentration of CloZAPine. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CycloSPORINE (Systemic): Omeprazole may increase the serum concentration of CycloSPORINE (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Moderate): May decrease the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inducers (Strong): May decrease the serum concentration of Omeprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Moderate): May increase the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C19 Inhibitors (Strong): May increase the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Cysteamine (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Cysteamine (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dacomitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dacomitinib.  Management: Avoid concurrent use of dacomitinib with PPIs and PCABs. Antacids may be used. Histamine H2-receptor antagonists (HR2A) may be used if dacomitinib is given at least 6 hours before or 10 hours after the H2RA.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Darunavir: May decrease the serum concentration of Omeprazole.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dasatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Dasatinib.  Management: Antacids (taken 2 hours before or after dasatinib administration) can be used in place of PPIs or PCABs if some acid-reducing therapy is needed.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Delavirdine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Delavirdine.  Management: Chronic therapy with PPIs or PCABs should be avoided in patients treated with delavirdine. The clinical significance of short-term PPI or PCAB therapy with delavirdine is uncertain, but such therapy should be undertaken with caution.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dextroamphetamine: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the absorption of Dextroamphetamine. Specifically, the dextroamphetamine absorption rate from mixed amphetamine salt extended release (XR) capsules may be increased in the first hours after dosing. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dichlorphenamide: OAT1/3 Inhibitors may increase the serum concentration of Dichlorphenamide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Doxycycline: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the bioavailability of Doxycycline. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Enoxacin: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Enoxacin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Erlotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Erlotinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Escitalopram: Omeprazole may increase the serum concentration of Escitalopram. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fosphenytoin-Phenytoin: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Fosphenytoin-Phenytoin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gefitinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Gefitinib.  Management: Avoid use of inhibitors of the proton pump (PPIs or PCABs) with gefitinib when possible. If required, administer gefitinib 12 hours after the PPI/PCAB or 12 hours before the next dose of the PPI/PCAB. Closely monitor clinical response to gefitinib.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Gliclazide: Omeprazole may increase the serum concentration of Gliclazide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies): Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Immune Checkpoint Inhibitors (Anti-PD-1, -PD-L1, and -CTLA4 Therapies). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Indinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Indinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Infigratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Infigratinib. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Infigratinib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Itraconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Itraconazole. This specifically applies to the super bioavailable itraconazole products (eg, Tolsura brand). Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Itraconazole. This specifically applies to the non-super bioavailable itraconazole products (eg, Sporanox brand and its generics).  Management: Exposure to Tolsura brand itraconazole may be increased by PPIs or PCABs ; consider itraconazole dose reduction. Exposure to Sporanox brand itraconazole may be decreased. Give Sporanox brand itraconazole at least 2 hrs before or 2 hrs after PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ketoconazole (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Ketoconazole (Systemic). Ketoconazole (Systemic) may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).  Management: Administer ketoconazole with an acidic beverage, such as non-diet cola, to increase gastric acidity and improve absorption if concomitant use with proton pump inhibitors or potassium-competitive acid blockers is necessary.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ledipasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Ledipasvir.  Management: PPI  or PCAB doses equivalent to omeprazole 20 mg or lower may be given with ledipasvir under fasted conditions. Use of ledipasvir with higher doses or with food, or 2 hours after a these agents, may reduce ledipasvir bioavailability.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Levoketoconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of Levoketoconazole. Levoketoconazole may increase the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C19 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mavacamten: CYP2C19 Inhibitors (Weak) may increase the serum concentration of Mavacamten.  Management: Start mavacamten at 5 mg/day if stable on a weak CYP2C19 inhibitor. For those stable on mavacamten who are initiating a weak CYP2C19 inhibitor, reduce mavacamten dose by one dose level.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methotrexate: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Methotrexate.  Management: Consider temporarily interrupting PPI or PCAB therapy in patients receiving high-dose methotrexate. If coadministered, monitor for increased methotrexate toxicity (eg, mucositis, myalgias) and/or delayed methotrexate elimination.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Moclobemide: May increase the serum concentration of Omeprazole. Omeprazole may increase the serum concentration of Moclobemide.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Multivitamins/Minerals (with ADEK, Folate, Iron): Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Multivitamins/Minerals (with ADEK, Folate, Iron). Specifically, the absorption of iron may be decreased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mycophenolate: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Mycophenolate. Specifically, concentrations of the active mycophenolic acid may be reduced. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nelfinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease serum concentrations of the active metabolite(s) of Nelfinavir. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nelfinavir.  Management: Due to potentially significant reductions in nelfinavir exposure, avoid concurrent use of nelfinavir with a PPI or PCAB when possible. If unavoidable, consider PPI or PCAB use for a short duration (less than 30 days) and closely monitor viral load.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Neratinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Neratinib. Specifically, proton pump inhibitors may reduce neratinib absorption. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nilotinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nilotinib.  Management: Avoid this combination. Histamine H2 receptor antagonists (H2RAs) given 10 hours before or 2 hours after nilotinib, or antacids given 2 hours before or 2 hours after nilotinib are acceptable alternatives.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Nirogacestat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Nirogacestat. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Octreotide: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Octreotide. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Palbociclib: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Palbociclib. Specifically, this has been reported with the use of palbociclib capsules. Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Palbociclib. Specifically, this may occur with the use of palbociclib capsules, and to the greatest extent when taken without food.  Management: Carefully evaluate potential risks and benefits of coadministration of palbociclib capsules and proton pump inhibitors or potassium-competitive acid blockers due to the risk of reduced palbociclib efficacy. Palbociclib capsules should be taken with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">PAZOPanib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of PAZOPanib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pexidartinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Pexidartinib.  Management: Avoid this combination. If acid-reduction is needed, consider administering an antacid 2 hours before or after pexidartinib, or administer pexidartinib 2 hours before or 10 hours after an H2 receptor antagonist.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Posaconazole: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Posaconazole.  Management: Avoid coadministration of PPIs or PCABs and posaconazole oral suspension. Posaconazole delayed-release tablets do not appear to be sensitive to this interaction and do not required dose adjustment if coadministered with PPIs or PCABs.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rilpivirine: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Rilpivirine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Riociguat: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Riociguat. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Risedronate: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the therapeutic effect of Risedronate. Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Risedronate. This applies specifically to use of delayed-release risedronate.  Management: Coadministration of PPIs or PCABs with delayed-release risedronate formulations is not recommended. Limit PPI/PCAB dose and duration during coadministration with risedronate as possible. Patients over age 70 are at higher risk of adverse effects.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Saquinavir: Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Saquinavir. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Secretin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Secretin. Specifically, use of PPIs may cause a hyperresponse in gastrin secretion in response to secretin stimulation testing, falsely suggesting gastrinoma.  Management: Avoid concomitant use of PPIs or PCABs and secretin, and discontinue PPI or PCAB several weeks prior to secretin administration, with the duration of separation determined by the specific acid suppressant. See full monograph for details.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selpercatinib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Selpercatinib.  Management: Coadministration of selpercatinib and PPIs or PCABs should be avoided. If coadministration cannot be avoided, selpercatinib and PPIs or PCABs should be administered simultaneously with food.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">SORAfenib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the absorption of SORAfenib. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sotorasib: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sotorasib. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sparsentan: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Sparsentan. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">St John's Wort: May decrease the serum concentration of Omeprazole.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tacrolimus (Systemic): Inhibitors of the Proton Pump (PPIs and PCABs) may increase the serum concentration of Tacrolimus (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Sestamibi: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Sestamibi.  Management: Consider holding/stopping proton pump inhibitor therapy for at least 3 days prior to the use technetium Tc 99m sestamibi in cardiac imaging procedures.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Technetium Tc 99m Tetrofosmin: Inhibitors of the Proton Pump (PPIs and PCABs) may diminish the diagnostic effect of Technetium Tc 99m Tetrofosmin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: Inhibitors of the Proton Pump (PPIs and PCABs) may enhance the adverse/toxic effect of Thiazolidinediones. Specifically, the risk of osteoporosis or fracture may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tipranavir: May decrease the serum concentration of Inhibitors of the Proton Pump (PPIs and PCABs). These data are derived from studies with Ritonavir-boosted Tipranavir.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Velpatasvir: Inhibitors of the Proton Pump (PPIs and PCABs) may decrease the serum concentration of Velpatasvir.  Management: Sofosbuvir/velpatasvir should be administered with food and taken 4 hours before omeprazole 20 mg. Sofosbuvir/velpatasvir/voxilaprevir can be administered with omeprazole 20 mg. Use with other PPIs or PCABs has not been studied.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Omeprazole may increase the serum concentration of Vitamin K Antagonists. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: Omeprazole may increase the serum concentration of Voriconazole. Voriconazole may increase the serum concentration of Omeprazole. <i> Risk C: Monitor therapy</i></p></div>
<div class="block foi drugH1Div" id="F203553"><span class="drugH1">Food Interactions</span>
<p style="text-indent:0em;text-align:justify;display:inline">Prolonged treatment (≥2 years) may lead to malabsorption of dietary vitamin B<sub>12</sub> and subsequent vitamin B<sub>12</sub> deficiency (Lam, 2013).</p></div>
<div class="block pri drugH1Div" id="F203542"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Outcome data following use of proton pump inhibitors (PPIs) during pregnancy are available (Choi 2023; Hussain 2022; Peron 2023). An increased risk of major congenital malformations has not been observed in available studies.</p>
<p style="text-indent:0em;margin-top:2em;">Recommendations for the treatment of gastroesophageal reflux disease in pregnant patients are available. When initiating treatment during pregnancy, a step-up approach, starting with diet and lifestyle modifications is recommended. PPIs are considered acceptable for use during pregnancy when other medications are not effective (Ali 2022; Dunbar 2022; Thélin 2020).</p></div>
<div class="block pha drugH1Div" id="F203520"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Proton pump inhibitor; suppresses gastric basal and stimulated acid secretion by inhibiting the parietal cell H+/K+ ATP pump</p></div>
<div class="block phk drugH1Div" id="F203538"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Note:</b> Half-life and AUC were significantly reduced for omeprazole suspension when compared with an equivalent dose via the commercially available capsule in 7 adults (Song 2001).</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Onset of action: Antisecretory: ~1 hour</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Peak effect: Within 2 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Duration: Up to 72 hours; 50% of maximum effect at 24 hours; after stopping treatment, secretory activity gradually returns over 3 to 5 days</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Maximum secretory inhibition: 4 days</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Absorption: Rapid</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Protein binding: ~95%</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Metabolism: Hepatic via CYP2C19 primarily and (to a lesser extent) via 3A4 to hydroxy, desmethyl, and sulfone metabolites (all inactive); saturable first-pass effect</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Bioavailability: Oral: ~30% to 40%; Hepatic dysfunction: ~100%; Asians: AUC increased up to fourfold compared to Caucasians</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Half-life elimination: 0.5 to 1 hour; hepatic impairment: ~3 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Time to peak, plasma: 0.5 to 3.5 hours</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Excretion: Urine (~77% as metabolites, very small amount as unchanged drug); feces</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Clearance: 500-600 mL/minute; chronic hepatic disease: 70 mL/minute </p></div>
<div class="block phksp drugH1Div" id="F51154917"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: There is slight increase in bioavailability in patients whose CrCl ranged between 10 and 62 mL/minute/1.73 m<sup>2</sup>.</p>
<p style="text-indent:-2em;margin-left:2em;">Hepatic function impairment: In patients with hepatic impairment (Child-Pugh class A, B, or C), bioavailability is increased ~100%, plasma half-life is increased, and plasma clearance is decreased.</p>
<p style="text-indent:-2em;margin-left:2em;">Older adult: The elimination rate is decreased; bioavailability is increased.</p>
<p style="text-indent:-2em;margin-left:2em;">Race/ethnicity: AUC is increased ~4-fold in Asian patients.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F203544"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Losec | Omapro | Omedar | Oprazole | Ozolex | Risek</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Aziatop | Brux | Fada omeprazol | Fendiprazol | Klomeprax | Losec | Oblisec | Omefar | Omeprasec | Omeprazol Dosa | Omeprazol Duncan | Omeprazol ilab | Omeprazol kilab | Omeprazol pharmavial | Omeprazol richet | Omeprazol Surar | Pravil | Regulacid | Stomacine | Timezol | Ulcozol | Zoltenk</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Antra | Losec | Omepralan | Omeprazol G L | Omeprazol Genericon | Omeprazol sandoz | Omeprazol stada</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Apo omeprazole | Chemists' own heartburn relief omeprazole | Chemmart omeprazole | Lontac heartburn relief | Losec | Maxor | Meprazol | Omepral | Omeprazole an | Omeprazole generichealth | Omeprazole Ranbxy | Omeprazole sandoz | Ozmep | Probitor | Terry white chemists omeprazole</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Aspra | Cosec | Eupi | Losectil | Omenix | Omenta | Omesil | Ometac | Op | Opal | Ppi | Prevas | Procap | Proceptin | Prolok | Prosectil | Seclo | Stosec | Xeldrin | Zoom</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Acidozol | Logastric | Losec | Losec mups | Omeprazole eurogenerics | Omeprazole Mylan | Omeprazole Teva</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Gasec | Ipeprazole | Ivepral | Lomac | Mopral | Omepral | Omizec | Philco mepra | Prazol | Proton | Sezol | Ulcizone</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Helicid | Losec | Omeprazol | Ortanol | Probitor | Sopral | Ulcoprol | Ultop</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Gaspiren | Losec | Lozeprel | Omeprasec | Omeprazol | Omeprazol sodica | Omeprazol sodico | Oprazon | Pratiprazol | Uniprazol | Victrix</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Amanol | Antra | Antramups | Antrapro | Omed | Omeprax | Omeprazol Helvepharm | Omeprazol mut | Omeprazol sandoz | Omeprazol Streuli | Omeprazol Teva | Omeprazol zentiva | Omeprazol-mepha | Omezol | Omezol mepha | Omezol mepha mt | Oprazol</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Alzole | Ipeprazole | Ipozole | Ipproton | Lomac | Omeprazole Generis | Omeshal | Omezol | Omoral | Oprazole | Prazol | Pylomex | Sezol | Solcer | Ulcizone</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Lomex | Losec | Togran | Zomepral</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">Ao li ya | Ao wei kang | Ao wei mei | Ao xi kang | Aoke | Bi si ke | Bisic | Fu luo xiang | Hai mei la | Jin ao kang | Ke di sheng | Kun li yu | Li ao jia | Li jun mei ao | Li wei ting | Lomac | Losec | Luo kai | Luo xin en kang | Omepral | Omeprazole | Oprazole | Ping fang shu | Shen li yu | Shuangqing ji li | Si wei ning | Wei quan</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Garmisch omex | Gastrosef | K delprazol | Lorigal | Losec | Olzol | Omeprazol | Omezol Lyo | Opraxol | Orazole | Pentren | Propisol | Prozidex | Rimaprazol | Sumicetron | Tarzol | Ulzone | Uprazol | Vomezal</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Apo ome | Gasec | Helicid | Lomac | Losec | Loseprazol | Moprilic | Omepirex | Omeprazol | Omeprazol aurovitas | Omeprazol e | Omeprazol Genim | Omeprazol mylan | Omeprazol olikla | Omeprazol Teva | Omeprol | Ortanol</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Antra | Gastracid | Gastrium | Omebeta | Omegamma | Omelich | Omep | Omep hexal | Omeprazol | Omeprazol abz | Omeprazol al | Omeprazol biomo | Omeprazol ct | Omeprazol Sandoz | Omeprazol stada | Omeprazol-ratiopharm nt</span>;</li>
<li>
<span class="countryCode">(DK)</span> <span class="country">Denmark</span><span class="countrySeparator">: </span><span class="drugName">Omelix | Omeprazol bmm pharma | Omeprazol pcd | Omeprazol ratiopharm</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Fendiprazol | Inhibitron | Losec | Lumeprazol | Lumeprazol m | Omeprazol | Omestop | Sanamidol</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Lomex | Losec | Omeprazol | Omez | Omezzol | Pentren | Prazolen | Risek | Tarzol | Ulcedon | Ulcozol</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Gasec | Losec | Losec mups | Ocid | Omep | Omeprazol | Omez | Ultop</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amelxess | Estohalt | Healsec | Hyposec | Losec | Napizole | Omepral | Omeprazole splended pharma | Omisec | Risek</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Arapride | Audazol | Indurgan | Losec | Mopral | Omapren | Omecura | Omeprazol Accord | Omeprazol Bayvit | Omeprazol Combino | Omeprazol Davur | Omeprazol farmamabo | Omeprazol Ges | Omeprazol Mede | Omeprazol Normon | Omeprazol stadapharm | Omeprazol ur | Parizac | Pepticum</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Aprazole | Cacid o | Eselan | Locid | Lokit | Medoprazole | Ome Far | Omecap | Omeprazol VIR | Omeprazole | Omipin | Omiz | Probitor | Prohibin | Remeprazole | Risek | Trisec</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Losec | Omeprazol Bluefish | Omeprazol Bmm</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Mopral | Mopralpro | Omeprazole abbott | Omeprazole Arrow | Omeprazole biogaran | Omeprazole bouchara recordati | Omeprazole gerda | Omeprazole Mylan | Zoltum</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Bertil | Heartburn relief | Losec | Maerta | Mepradec | Mezzopram | Omeprazol xiromed | Omeprazole | Omeprazole kent | Omeprazole sandoz | Omeran | Pyrocalm control | Zanprol</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Acromon | Alevior | Assoprol | Efrozin | Elcodrop | Elcontrol | Elkomed | Eselan | Esopraz | Ezipol | Lanex | Lenar | Lomezec | Loproc | Lordin | Losec | Lyopraz | Malortil | Meprolen | Odasol | Ofnimarex | Omeprazole | Omeprazole Specifar | Omeprazole/alvia | Omeprazole/generics | Omeprazole/teva | Omeprol | Omerane | Penrazol | Pip acid | Rukuz | Rythmogastryl | Sodeprol | Ufonitren | Veralox | Zolandil</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Elkotheran | Eprazole | Ezipol | Gasec | Lomac | Losec | Marsec | Omekaa | Omesac | Omesec | Omz | Seclo | Ultop</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Omezol | Ortalox | Ortanol | Target | Ultop | Ulzol</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Crismel | Losec | Ludea | Omeprazol-ratiopha</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Contral | Dudencer | Gastrofer | Gibancer | Inhipump | Lokev | Loklor | Losec | Meisec | Morecon | Norsec | Omeprazole | Omz | Onic | Oprezol | Ozid | Prohibit | Protop | Pumpitor | Redusec | Rindopump | Risek | Rocer | Socid | Stomacer | Tamezol | Zeprazol</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Losamel | Losec | Losepine | Ulcid</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Omepradex</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Amizole | Coolfresh | Elcid od | Erozole | Lyom | Mago | Nabizole | Ocid | Olzole | Omcar | Ome ppi | Omecip | Omef 20 | Omefol | Omefor | Omeg | Omegold | Omenat | Ometab | Omey | Omez | Omezee | Omezole | Omifyl | Onto | Opera | Opnav | Oprazole | Oskar | Ozo | Pezo | Poraz | Prilosid | Protoloc | Romesec | Stamirich | Tacko-m | Tom | Ultop | Zomac | Zosec-m</span>;</li>
<li>
<span class="countryCode">(IQ)</span> <span class="country">Iraq</span><span class="countrySeparator">: </span><span class="drugName">Omeprazol | Omeprazole awa | Omeprosaf | Oprazon | Pioprazole</span>;</li>
<li>
<span class="countryCode">(IS)</span> <span class="country">Iceland</span><span class="countrySeparator">: </span><span class="drugName">Lomex</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Antra | Ibimezolo | Omeprazolo | Omeprazolo Angenerico | Omeprazolo Fg | Omeprazolo mylan | Omeprazolo Sandoz | Xantrazol</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Ipproton | Lordin | Losec | Odasol | Omedar | Omisec | Oprazole | Risek</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Enpral | Omepral | Omeprazole | Omeprazole amel | Omeprazole asahi kasei pharma | Omeprazole merck hoei | Omeprazole sandoz | Omeprazole sawai | Omeprazole towa | Omeprazon | Omeproton | Omeptorol | Omerap | Ovulanze</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Asid | Belifax | Dawapraz | Epirazole | Gasec | Gracid | Locid | Lokit | Lomizol | Losec | Losec mups | Ocid | Ocid qrs | Om | Omapez | Omecos | Omegut | Omemark | Omenix | Omepraglobe | Omepraz | Omeprazole agio | Omesk | Omez | Omezole | Omfil | Ominext | Omipin | Omis | Omisec | Omizec | Omlink | Ommed | Omz | Onpraz | Opraz | Poraz | Proceptin | Prohibin | Pylomex | Risek | Trisec | Ulsec | Ulzol | Unimez | Uniprazole | Uprone | Virom | Zep | Zocid | Zosec</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Besprazole | Losec | Meprazole | Neusec | Ocuzole | Ome q | Omed | Omeprazon | Omepuzole | Omerapin | Ometone | Omezone | Omp | Result | Ulpro | Wonmp</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Omedar | Oprazole | Risek</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Epirazole | Gastrazole | Gastrimut | Gastrisec | Glaveral | Ipproton | Losec | Lozicare | Omedar | Omepral | Omeprazole | Omeprazole Arrow | Ometon | Omizec | Oprazole | Risek | Sanamidol | Ulcazal | Zimor</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Gasec | Losec | Ocid | Olezela | Omep | Omeprazol nord | Omeprazol stada | Omeprol | Omez | Omizac | Ultop</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Losec | Omeprazole eg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Gasec | Lomac | Losec | Ocid | Omebel | Omeira | Omeprazol sandoz | Ultop</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Kalest | Mopral | Mozal | Oedes | Omeprazole normon</span>;</li>
<li>
<span class="countryCode">(MT)</span> <span class="country">Malta</span><span class="countrySeparator">: </span><span class="drugName">Gasec</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Acenorol | Aclopec | Aktyzar | Cenul | Cubrelac | Drivewell | Finulcer | Fluxavit | Gerdex | Haitrax | Ibax | Ibemiral | Inhibitron | Inhibitron f | Lopram | Losec | Losec a | Lozarbru | Omecaps | Omeprazol | Omeprazol loeffler | Omeprazol Solara | Omygen | Ozapravit | Parlanol | Pastrizol | Pentren | Prazidec i | Prezolax | Promezal | Sarox | Solcer | Suifac | Tarzol | Ucetal | Ulsen | Ultizol | Wayomer | Zolufen</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Gastrazole | Lomax | Losec | Medoprazole | Omelon | Omeprazole | Omez | Omezol Lyo | Vaxcel omeprazole | Zefxon</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Ac ome | Acidux | Anseprazole | Ardemag omeprazole | Aveprazole | Bondpraz | Chimexbon omeprazole | Corcid | Deczol | Derm omeprazole | Dilazol | Dosky | Duogasrol | Elarkzole | Emek jiors omeprazole | Eprazole | Galen's omeprazole | Gastrisafe | Getzome | Glomeprex | Gloprozole | Healthpath omeprazole | Intracell's omeprazole | Juoprezol | Lefazole | Lemloc | Liricon omeprazole | Losec mups | Mediprazo | Meem omeprazole | Mepravo | Meprol | Myfil omeprazole | Nasazole | Nelb omeprazole | Nemelprazone | Norprazole | Odasol | Olarox | Olit | Omecap | Omecid | Omefast | Omepass | Omepep | Omepra j | Omeprazoe | Omeprazole | Omeprazole makinga | Omesaint | Omester | Omesuit | Omisyn | Omlink | Ompalen | Onifam omeprazole | Oprazol | Oropral | Osymeprazole | Ozeco | Ozila omeprazole | Pal omeprazole | Ricnos omeprazole | Rivaprazole | Roviprazole | Rumaprazole | Sd omeprazole | Seramol | Shinfield omeprazole | Simbzole | Softhealth omeprazole | Soloprazole | Solpraz | Somepra | Spectrazole | Sunymet omeprazole | Talibex omeprazole | Taurazole | Teka omeprazole | Ugazole | Viprax | Wellcare omeprazole</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Itomed | Losec | Losec mups | Losecosan | Omepraphar | Omeprazol | Omeprazol A | Omeprazol actavis | Omeprazol Alpharma | Omeprazol Cf | Omeprazol Katwijk | Omeprazol PCH | Omeprazol ratiopharm</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Losec | Losec mups | Omeprazol</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Drreddys omeprazole | Losec | Ocicure | Omeprazole | Omezol</span>;</li>
<li>
<span class="countryCode">(OM)</span> <span class="country">Oman</span><span class="countrySeparator">: </span><span class="drugName">Omapro</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Biopral b | Monoprazol | Norprazole | Omepra n | Omepramed | Omepraxina | Omeprazol | Omeprazol panalab | Ometab | Omez | Omzol | Xipatem pd</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acifre | Acipraz | Aeprazole | Altoprazole | Cerol | Cleazole | Cylic | Diapraz | Eastprazol | Empraz | Ezrazole | Ficuzole | Frazole | Gastrilife | Gastriloc | Gemzole | Genzole | Geoprazole | Gezole | Gomeprazole | Gopraz iv | Goprazole | Hovizol | Hyperzol | Inhibita | Kairozol | Leveprazole | Lomezek | Lopep | Losec | Marprazole | Mepzopraz | Merazol | Neoverzol | Newpron | Omcare | Omecise | Omed | Omefil | Omegut | Omeline | Omemac Gerd | Omenole | Omepfind | Omephar | Omeprazole | Omepron | Omeproviv | Omepzol | Omera | Omesan | Omesar | Omesel | Omestop | Ometec | Ometor | Omevex | Omexac | Omexol | Omez | Omezid | Omezol | Omipra | Omizac | Omlek | Ompraz | Opehex | Opraz | Peptisolv | Perazole | Plosek | Pramiz | Premio | Promeprazole | Prosec | Protonblock | Qualiprazole | Ranzole | Risek | Seaprazole | Sidprazole | Somecid | Soprazole | Suprezol | Tansinel | Ulcomez | Ulsek | Viprazo | Zefxon | Zemomax | Zevar | Zomep | Zosec | Zyom</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Amazole | Aromep | Astezol | Aveome | Benzim | Brizole | Calsic | Capzol | Cidpro | Cisec | Coozip | Delka | Dits | Elzed | Emperole | Encid | Eselan | Etipro | Exocid | Faast | Fymezole | Glaveral | Gotec | Healium | Healom | Helezol | I care | Invenzol | Jumep | Leprozim | Loprot | Losec | Lovanzo | Lozal | Lozena | Mep | Meprawin | Meprazol | Mozole | Nafzole | Neusec | Noctis | Nomizil | Olit | Olx | Om fresh | Oma | Ome ec | Ome stoch | Omec | Omed | Omega | Omepratin | Omera | Omeris | Omesec | Ometec | Ometek | Omezol | Omir | Omium | Omizac | Omnat | Omol | Omp | Omtane | Opepzole | Operitec | Opra | Oprazol | Oprime | Oray | Oraz | Orgid | Osimep | Ospra | Otaso | Prazol | Proced | Profile | Promiz | Protole | Re zool | Reflux | Refuge | Remezon | Saimep | Sanamidol | Seclo | Shalay | Sunder | Teph | Tesso | Timezol | U mip | Ul-rid | Vify | Vrochi | Vyber | Weprazol | Winpro | Winzek | Xopra | Xtinct | Zapra | Zaprole | Zegna | Zegrid | Zepep plus | Zolat | Zoltar | Zoprol</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Agastin | Bioprazol bio control | Gasec | Groprazol | Helicid | Losec | Loseprazol | Notis | Nozer | Omar | Omepragal | Omeprazol mylan | Omeprazol Teva | Omeprazol-egis | Omeprazole genoptim | Omeprazole Mercapharm | Ortanol | Polprazol | Prazigast | Prazol | Prazol neo | Ulzol | Ventazol</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Omeprazole Delayed Release | Prilosec</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Gasec | Losec | Omeprazol | Omeprazol azevedos | Omeprazol Basi | Omeprazol cinfa | Omeprazol Generis | Omeprazol mylan | Omeprazol tecnigen | Omeprazol vitoria | Ometon | Omezolan | Prazolene | Proclor</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Clanzol | Digezimas | Faboacid plus | Fendiprazol | Gasipral | Gastricalm | Gastricet | Gastropax | Gastropax nf | Klomeprax | Lomex | Ome gastrin | Omepan | Omeprasec | Omeprazol bioethic | Omeprazol bioethic pharma | Omeprazol bioteng | Omeprazol caplin point | Omeprazol cellofarm | Omeprazol dallas | Omeprazol demotek | Omeprazol emcure | Omeprazol eurofarma | Omeprazol fada pharma | Omeprazol gautier | Omeprazol genfar | Omeprazol imedic | Omeprazol klonal | Omeprazol la sante | Omeprazol millet | Omeprazol mintlab | Omeprazol polimed | Omeprazol richet | Omeprazol sandoz | Omeprazol savant pharm | Omezol | Perval | Pronezol | Sompraz | Timezol | Ulcozol | Vilox</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Aciloc (Jamjoom) | Emilok | Epirazole | Gasec | Gastrozole | Hyposec | Losec | Losec MUPS | Minisec | Omapro | Omedar | Omepak | Omeprex | Omeral | Omezyn-20 | Omezyn-40 | Omisec | Omisec IV | Omiz | Oprazole | R-Omez | Risek | Risek IV | Ulcazal | Ulceral | Ulstop</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Helicid | Omedar | Omeprazol atb | Omeprazol aurobindo | Omeran | Omez</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Cisagast | Gastrozol | Gelcizol | Helicid | Helol | Lomac | Losec | Omal | Omeprazol | Omeprazole youcare | Omeprol | Omeprus | Omez | Omipix | Omitox | Omizac | Ortanol | Promez | Romesec | Sopral | Ulcozol | Ultop | Vero omeprazol | Zerocid | Zolcer</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Ipproton | Losec | Omecure | Omedar | Omisec | Omiz | Oprazole | Risek | Sedacid</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Losec | Omeprazol Abcur | Omeprazol apofri | Omeprazol arrow | Omeprazol aurobindo | Omeprazol Merck NM</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Losec | Ocid | Olit | Omenole | Omepradex | Omeprazole | Omesec | Omezol | Omezole | Omicap | Proceptin | Pumpitor | Romesec | Zimor</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Losec | Ortanol | Ultop | Ultop S</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Asilar | Crismel | Helicid | Losec | Omeprazol | Omeprazol sandoz | Omeprazol Teva | Omeprol | Omera | Oprazole</span>;</li>
<li>
<span class="countryCode">(SL)</span> <span class="country">Sierra Leone</span><span class="countrySeparator">: </span><span class="drugName">Ompalen | Omprez | Ronzole | Uprone | Wl gacid</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amnopra | Cazec | Eselan | Gerdex | Losec | O Sid | Ocid | Omeman | Omeppi | Omesec | Omez | Omezol Lyo | Omicid | Omizole | Omp | Somecid | Ulsec | Zefxon</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Gastral | Ipproton | Oprazole | Risek</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Erbinna | Eselan | Gastromax | Losec | Loseprol | Olmezol | Omepreful | Omeprol | Omeref</span>;</li>
<li>
<span class="countryCode">(TT)</span> <span class="country">Trinidad and Tobago</span><span class="countrySeparator">: </span><span class="drugName">Gasec</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Biozole | Lometin | Okwe | Omepron | Omezol</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Diaprasol | Diaprazol | Elkotheran | Losec | Ocid | Omealox | Omenax | Omep | Omepraz | Omeprazol | Omeprazol astrapharm | Omeprazole | Omeprazole pharmac | Omez | Omezin | Omzol | Oprazol | Ozol | Proyaz | Romesek | Ulkoprol | Ultop | Zerocid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Agom | Asid | Belifax | Cacid o | Lomac | Loprot | Ocid | Omepric | Omepsun | Omezing | Omipin | Omipix | Omlink | Poraz | Prohibin | Pumpitor | Risek | Solcer | Ulsec</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Fremalt | Gastricet | Losec | Losec mups | Omepracid | Omeprasec | Omeprazol | Omeprazol blau farmaceutica | Omeprazol pharmavial</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aziatop | Losec | Ocicure | Omebloc | Omeflux | Omenax | Omeprasec | Omeprazol | Omeprazol sodico | Omepruni | Omerol | Omesan | Omestop | Oprazol | Pentren</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Ag ome | Agimepzol | Atimezon | Auzomek | Hatrizol | Helinzole | Kagasdine | Lasectil | Lymezol | Medinpacol | Omaza | Omecaplus | Omeptul | Omevin | Ommax | Oracap | Oraptic | Pyomezol | VacoOmez | Virazom</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Omeprazole | Adco-omeprazole | Altosec | Lokit | Lokit dr | Lokit otc | Losec | Omeprazole safeline | Rapacid</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Aprazole | Asid | Lokit | Lomez | O mar | Olit | Omecid | Omeshal | Omezole | Omfil | Omizac | Omlink | Ompalen | Poraz | Prohibin | Ryvazole | Ulzol | Zolcer | Zomacid | Zosec</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Omizac | Zomacid</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22697020">
<a name="22697020"></a>Abdul Razzak E, Tomás M, Tornero P, Herrero T. Nine cases of allergy to omeprazole. <i>J Investig Allergol Clin Immunol</i>. 2012;22(3):228-230.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22697020/pubmed" id="22697020" target="_blank">22697020</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23010681">
<a name="23010681"></a>Abraham NS. Proton pump inhibitors: potential adverse effects. <i>Curr Opin Gastroenterol</i>. 2012;28(6):615-620. doi:10.1097/MOG.0b013e328358d5b9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23010681/pubmed" id="23010681" target="_blank">23010681</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21060077">
<a name="21060077"></a>Abraham NS, Hlatky MA, Antman EM, et al; ACCF/ACG/AHA. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on Expert Consensus Documents. <i>Circulation.</i> 2010;122(24):2619-2633. doi: 10.1161/CIR.0b013e318202f701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21060077/pubmed" id="21060077" target="_blank">21060077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24507954">
<a name="24507954"></a>Adams AL, Black MH, Zhang JL, Shi JM, Jacobsen SJ. Proton-pump inhibitor use and hip fractures in men: a population-based case-control study. <i>Ann Epidemiol</i>. 2014;24(4):286-290. doi:10.1016/j.annepidem.2014.01.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24507954/pubmed" id="24507954" target="_blank">24507954</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23425521">
<a name="23425521"></a>Agewall S, Cattaneo M, Collet JP, et al; ESC Working Group on Cardiovascular Pharmacology and Drug Therapy and ESC Working Group on Thrombosis. Expert position paper on the use of proton pump inhibitors in patients with cardiovascular disease and antithrombotic therapy. <i>Eur Heart J</i>. 2013;34(23):1708-1713, 1713a-1713b. doi: 10.1093/eurheartj/eht042<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23425521/pubmed" id="23425521" target="_blank">23425521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27398293">
<a name="27398293"></a>Aggarwal N. Drug-induced subacute cutaneous lupus erythematosus associated with proton pump inhibitors. <i>Drugs Real World Outcomes</i>. 2016;3(2):145-154. doi:10.1007/s40801-016-0067-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/27398293/pubmed" id="27398293" target="_blank">27398293</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11487763">
<a name="11487763"></a>Ahlfors CE. Benzyl alcohol, kernicterus, and unbound bilirubin. <i>J Pediatr</i>. 2001;139(2):317-319.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11487763/pubmed" id="11487763" target="_blank">11487763</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35508989">
<a name="35508989"></a>Ali RAR, Hassan J, Egan LJ. Review of recent evidence on the management of heartburn in pregnant and breastfeeding women. <i>BMC Gastroenterol</i>. 2022;22(1):219. doi:10.1186/s12876-022-02287-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/35508989/pubmed" id="35508989" target="_blank">35508989</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23548825">
<a name="23548825"></a>Almebayadh M, Regnier-Rosencher E, Carlotti A, et al. Subacute cutaneous lupus erythematosus induced and exacerbated by proton pump inhibitors. <i>Dermatology</i>. 2013;226(2):119-123. doi:10.1159/000346694<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23548825/pubmed" id="23548825" target="_blank">23548825</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28045707">
<a name="28045707"></a>American Society of Anesthesiologists (ASA). Practice guidelines for preoperative fasting and the use of pharmacologic agents to reduce the risk of pulmonary aspiration: application to healthy patients undergoing elective procedures: an updated report by the American Society of Anesthesiologists Task Force on Preoperative Fasting and the Use of Pharmacologic Agents to Reduce the Risk of Pulmonary Aspiration. <i>Anesthesiology</i>. 2017;126(3):376-393. doi: 10.1097/ALN.0000000000001452.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28045707/pubmed" id="28045707" target="_blank">28045707</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10690219">
<a name="10690219"></a>American Society of Health-System Pharmacists. ASHP therapeutic guidelines on stress ulcer prophylaxis. <i>Am J Health Syst Pharm</i>. 1999;56(4):347-379. doi: 10.1093/ajhp/56.4.347<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10690219/pubmed" id="10690219" target="_blank">10690219</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27060684">
<a name="27060684"></a>Anderson PO, Sauberan JB. Modeling drug passage into human milk. <i>Clin Pharmacol Ther</i>. 2016;100(1):42-52. doi:10.1002/cpt.377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/27060684/pubmed" id="27060684" target="_blank">27060684</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11095324">
<a name="11095324"></a>Andersson T, Hassall E, Lundborg P, et al, "Pharmacokinetics of Orally Administered Omeprazole in Children. International Pediatric Omeprazole Pharmacokinetic Group," <i>Am J Gastroenterol</i>, 2000, 95(11):3101-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11095324/pubmed" id="11095324" target="_blank">11095324</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8995942">
<a name="8995942"></a>Balaban DH, Duckworth CW, and Peura DA, "Nasogastric Omeprazole: Effects on Gastric pH in Critically Ill Patients," <i>Am J Gastroenterol</i>, 1997, 92(1):79-83.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/8995942/pubmed" id="8995942" target="_blank">8995942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31634917">
<a name="31634917"></a>Barkun AN, Almadi M, Kuipers EJ, et al. Management of nonvariceal upper gastrointestinal bleeding: guideline recommendations from the International Consensus Group. <i>Ann Intern Med</i>. 2019;171(11):805-822. doi:10.7326/M19-1795<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31634917/pubmed" id="31634917" target="_blank">31634917</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27163192">
<a name="27163192"></a>Barletta JF, Bruno JJ, Buckley MS, Cook DJ. Stress ulcer prophylaxis. <i>Crit Care Med</i>. 2016;44(7):1395-1405. doi: 10.1097/CCM.0000000000001872<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/27163192/pubmed" id="27163192" target="_blank">27163192</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21640290">
<a name="21640290"></a>Bell AD, Roussin A, Cartier R, et al, “The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,” <i>Can J Cardiol</i>, 2011, 27(Suppl A):1-59.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21640290/pubmed" id="21640290" target="_blank">21640290</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30058396">
<a name="30058396"></a>Benito-Garcia F, Chambel M, Morais-Almeida M. Anaphylaxis due to proton pump inhibitors: current understanding and important clinical considerations. <i>Expert Rev Clin Immunol</i>. 2018;14(8):653-656. doi:10.1080/1744666X.2018.1505504<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/30058396/pubmed" id="30058396" target="_blank">30058396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bergsland.2020">
<a name="Bergsland.2020"></a>Bergsland E. Management and prognosis of the Zollinger-Ellison syndrome (gastrinoma). Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 23, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24629073">
<a name="24629073"></a>Berney-Meyer L, Hung N, Slatter T, Schollum JB, Kitching AR, Walker RJ. Omeprazole-induced acute interstitial nephritis: a possible Th1-Th17-mediated injury? <i>Nephrology (Carlton)</i>. 2014;19(6):359-365. doi:10.1111/nep.12226<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24629073/pubmed" id="24629073" target="_blank">24629073</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7819941">
<a name="7819941"></a>Beutler M, Hartmann K, Kuhn M, Gartmann J. Arthralgias and omeprazole. <i>BMJ</i>. 1994;309(6969):1620. doi:10.1136/bmj.309.6969.1620<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/7819941/pubmed" id="7819941" target="_blank">7819941</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28401712">
<a name="28401712"></a>Bhana A, Waters MJ, Fazal MW, Kimber T. Pantoprazole-induced hypomagnesaemia causing cerebellar syndrome and seizures. <i>Intern Med J</i>. 2017;47(4):467-468. doi:10.1111/imj.13388<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28401712/pubmed" id="28401712" target="_blank">28401712</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20925534">
<a name="20925534"></a>Bhatt DL, Cryer BL, Contant CF, et al; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. <i>N Engl J Med</i>. 2010;363(20):1909-1917. doi: 10.1056/NEJMoa1007964<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20925534/pubmed" id="20925534" target="_blank">20925534</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30558872">
<a name="30558872"></a>Blumenthal KG, Peter JG, Trubiano JA, Phillips EJ. Antibiotic allergy. <i>Lancet</i>. 2019;393(10167):183-198. doi:10.1016/S0140-6736(18)32218-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/30558872/pubmed" id="30558872" target="_blank">30558872</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Bonis.1">
<a name="Bonis.1"></a>Bonis PAL, Gupta SK. Treatment of eosinophilic esophagitis. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 25, 2021.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9317099">
<a name="9317099"></a>Borum ML, Cannava M. Diffuse alopecia associated with omeprazole. <i>Am J Gastroenterol</i>. 1997;92(9):1576.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9317099/pubmed" id="9317099" target="_blank">9317099</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24267357">
<a name="24267357"></a>Bose S, Guyer A, Long A, Banerji A. Evaluation and management of hypersensitivity to proton pump inhibitors. <i>Ann Allergy Asthma Immunol</i>. 2013;111(6):452-457. doi:10.1016/j.anai.2013.08.022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24267357/pubmed" id="24267357" target="_blank">24267357</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7999487">
<a name="7999487"></a>Boulay K, Blanloeil Y, Bourveau M, Geay G, Malinovsky JM. Effects of oral ranitidine, famotidine and omeprazole on gastric volume and pH at induction and recovery from general anaesthesia. <i>Br J Anaesth</i>. 1994;73(4):475-478. doi: 10.1093/bja/73.4.475<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/7999487/pubmed" id="7999487" target="_blank">7999487</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24751668">
<a name="24751668"></a>Bourneau-Martin D, Leclech C, Jamet A, et al. Omeprazole-induced drug reaction with eosinophilia and systemic symptoms (DRESS). <i>Eur J Dermatol</i>. 2014;24(3):413-415. doi:10.1684/ejd.2014.2343<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24751668/pubmed" id="24751668" target="_blank">24751668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8159596">
<a name="8159596"></a>Bowlby HA, Dickens GR. Angioedema and urticaria associated with omeprazole confirmed by drug rechallenge. <i>Pharmacotherapy</i>. 1994;14(1):119-122. doi:10.1002/j.1875-9114.1994.tb02796.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/8159596/pubmed" id="8159596" target="_blank">8159596</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26120552">
<a name="26120552"></a>Brockow K, Przybilla B, Aberer W, et al. Guideline for the diagnosis of drug hypersensitivity reactions: S2K-Guideline of the German Society for Allergology and Clinical Immunology (DGAKI) and the German Dermatological Society (DDG) in collaboration with the Association of German Allergologists (AeDA), the German Society for Pediatric Allergology and Environmental Medicine (GPA), the German Contact Dermatitis Research Group (DKG), the Swiss Society for Allergy and Immunology (SGAI), the Austrian Society for Allergology and Immunology (ÖGAI), the German Academy of Allergology and Environmental Medicine (DAAU), the German Center for Documentation of Severe Skin Reactions and the German Federal Institute for Drugs and Medical Products (BfArM). <i>Allergo J Int</i>. 2015;24(3):94-105. doi:10.1007/s40629-015-0052-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/26120552/pubmed" id="26120552" target="_blank">26120552</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11341670">
<a name="11341670"></a>Brunner G, Athmann C, Boldt JH. Reversible pheripheral edema in female patients taking proton pump inhibitors for peptic acid diseases. <i>Dig Dis Sci</i>. 2001;46(5):993-996. doi:10.1023/a:1010745624971<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11341670/pubmed" id="11341670" target="_blank">11341670</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16651285">
<a name="16651285"></a>Canani RB, Cirillo P, Roggero P, et al, "Therapy With Gastric Acidity Inhibitors Increases the Risk of Acute Gastroenteritis and Community-Acquired Pneumonia in Children," <i>Pediatrics</i>, 2006, 117(5):e817-20.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/16651285/pubmed" id="16651285" target="_blank">16651285</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28842261">
<a name="28842261"></a>Cao F, Chen CX, Wang M, et al. Updated meta-analysis of controlled observational studies: proton-pump inhibitors and risk of Clostridium difficile infection. <i>J Hosp Infect</i>. 2018;98(1):4-13. doi:10.1016/j.jhin.2017.08.017<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28842261/pubmed" id="28842261" target="_blank">28842261</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30675130">
<a name="30675130"></a>Casciaro M, Navarra M, Inferrera G, Liotta M, Gangemi S, Minciullo PL. PPI adverse drugs reactions: a retrospective study. <i>Clin Mol Allergy</i>. 2019;17:1. Published 2019 Jan 18. doi:10.1186/s12948-019-0104-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/30675130/pubmed" id="30675130" target="_blank">30675130</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-6810084">
<a name="6810084"></a>Centers for Disease Control (CDC). Neonatal deaths associated with use of benzyl alcohol—United States. <i>MMWR Morb Mortal Wkly Rep</i>. 1982;31(22):290-291. <a href="https://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm" target="_blank">http://www.cdc.gov/mmwr/preview/mmwrhtml/00001109.htm</a>
<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/6810084/pubmed" id="6810084" target="_blank">6810084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24935270">
<a name="24935270"></a>Chalasani NP, Hayashi PH, Bonkovsky HL, et al. ACG Clinical Guideline: the diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2014;109(7):950-967. doi:10.1038/ajg.2014.131<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24935270/pubmed" id="24935270" target="_blank">24935270</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929376">
<a name="33929376"></a>Chalasani NP, Maddur H, Russo MW, Wong RJ, Reddy KR; Practice parameters Committee of the American College of Gastroenterology. ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury. <i>Am J Gastroenterol</i>. 2021;116(5):878-898. doi:10.14309/ajg.0000000000001259<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/33929376/pubmed" id="33929376" target="_blank">33929376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11274623">
<a name="11274623"></a>Chan FK, Chung SC, Suen BY, et al. Preventing recurrent upper gastrointestinal bleeding in patients with <i>Helicobacter pylori</i> infection who are taking low-dose aspirin or naproxen. <i>N Engl J Med</i>. 2001;344(13):967-973. doi: 10.1056/NEJM200103293441304<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11274623/pubmed" id="11274623" target="_blank">11274623</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26108134">
<a name="26108134"></a>Cheungpasitporn W, Thongprayoon C, Kittanamongkolchai W, et al. Proton pump inhibitors linked to hypomagnesemia: a systematic review and meta-analysis of observational studies. <i>Ren Fail</i>. 2015;37(7):1237-1241. doi:10.3109/0886022X.2015.1057800<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/26108134/pubmed" id="26108134" target="_blank">26108134</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28071659">
<a name="28071659"></a>Chey WD, Leontiadis GI, Howden CW, Moss SF. ACG clinical guideline: treatment of <i>Helicobacter pylori</i> infection. <i>Am J Gastroenterol</i>. 2017;112(2):212-239. doi: 10.1038/ajg.2016.563<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28071659/pubmed" id="28071659" target="_blank">28071659</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17608775">
<a name="17608775"></a>Chey WD, Wong BC, et al. American College of Gastroenterology Guideline on the Management of <i>Helicobacter pylori</i> Infection. <i>Am J Gastroent.</i> 2007;102(8):1808-1825.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/17608775/pubmed" id="17608775" target="_blank">17608775</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36626173">
<a name="36626173"></a>Choi A, Noh Y, Jeong HE, et al. Association Between Proton Pump Inhibitor Use During Early Pregnancy and Risk of Congenital Malformations. <i>JAMA Netw Open</i>. 2023;6(1):e2250366. doi:10.1001/jamanetworkopen.2022.50366<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/36626173/pubmed" id="36626173" target="_blank">36626173</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23134998">
<a name="23134998"></a>Chularojanamontri L, Jiamton S, Manapajon A, et al. Cutaneous reactions to proton pump inhibitors: a case-control study. <i>J Drugs Dermatol</i>. 2012;11(10):e43-e47.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23134998/pubmed" id="23134998" target="_blank">23134998</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25752807">
<a name="25752807"></a>Cohen S, Bueno de Mesquita M, Mimouni FB. Adverse effects reported in the use of gastroesophageal reflux disease treatments in children: a 10 years literature review. <i>Br J Clin Pharmacol</i>. 2015;80(2):200-208. doi:10.1111/bcp.12619<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/25752807/pubmed" id="25752807" target="_blank">25752807</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16440530">
<a name="16440530"></a>Confino-Cohen R, Goldberg A. Anaphylaxis to omeprazole: diagnosis and desensitization protocol. <i>Ann Allergy Asthma Immunol</i>. 2006;96(1):33-36. doi:10.1016/S1081-1206(10)61037-X<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/16440530/pubmed" id="16440530" target="_blank">16440530</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1682578">
<a name="1682578"></a>Convens C, Verhelst J, Mahler C. Painful gynaecomastia during omeprazole therapy. <i>Lancet</i>. 1991;338(8775):1153. doi:10.1016/0140-6736(91)92018-w<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/1682578/pubmed" id="1682578" target="_blank">1682578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15818102">
<a name="15818102"></a>Conrad SA, Gabrielli A, Margolis B, et al. Randomized, double-blind comparison of immediate-release omeprazole oral suspension versus intravenous cimetidine for the prevention of upper gastrointestinal bleeding in critically ill patients. <i>Crit Care Med</i>. 2005;33(4):760-765. doi: 10.1097/01.ccm.0000157751.92249.32<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/15818102/pubmed" id="15818102" target="_blank">15818102</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9768533">
<a name="9768533"></a>Cooper BT, Neumann CS, Cox MA, Iqbal TH. Continuous treatment with omeprazole 20 mg daily for up to 6 years in Barrett's oesophagus. <i>Aliment Pharmacol The</i>r. 1998;12(9):893-897. doi: 10.1046/j.1365-2036.1998.00389.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9768533/pubmed" id="9768533" target="_blank">9768533</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20353792">
<a name="20353792"></a>Corley DA, Kubo A, Zhao W, Quesenberry C. Proton pump inhibitors and histamine-2 receptor antagonists are associated with hip fractures among at-risk patients. <i>Gastroenterology</i>. 2010;139(1):93-101. doi:10.1053/j.gastro.2010.03.055<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20353792/pubmed" id="20353792" target="_blank">20353792</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31378636">
<a name="31378636"></a>Corley DA. Safety and complications of long-term proton pump inhibitor therapy: getting closer to the truth. <i>Gastroenterology</i>. 2019;157(3):604-607. doi:10.1053/j.gastro.2019.07.039<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31378636/pubmed" id="31378636" target="_blank">31378636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Crowe.2020">
<a name="Crowe.2020"></a>Crowe SE. Treatment regimens for Helicobacter pylori. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed February 6, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9692687">
<a name="9692687"></a>Cullen D, Bardhan KD, Eisner M, et al. Primary gastroduodenal prophylaxis with omeprazole for non-steroidal anti-inflammatory drug users. <i>Aliment Pharmacol Ther</i>. 1998;12(2):135-140. doi: 10.1046/j.1365-2036.1998.00288.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9692687/pubmed" id="9692687" target="_blank">9692687</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18221401">
<a name="18221401"></a>Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. <i>Clin Endocrinol (Oxf)</i>. 2008;69(2):338-341. doi:10.1111/j.1365-2265.2008.03194.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/18221401/pubmed" id="18221401" target="_blank">18221401</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18176768">
<a name="18176768"></a>Dam C, Bygum A. Subacute cutaneous lupus erythematosus induced or exacerbated by proton pump inhibitors. <i>Acta Derm Venereol</i>. 2008;88(1):87-89. doi:10.2340/00015555-0335<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/18176768/pubmed" id="18176768" target="_blank">18176768</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10852086">
<a name="10852086"></a>DiGiacinto JL, Olsen KM, Bergman KL, et al, “Stability of Suspension Formulations of Lansoprazole and Omeprazole Stored in Amber-Colored Plastic Oral Syringes,” <i>Ann Pharmacother</i>, 2000, 34(5):600-5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10852086/pubmed" id="10852086" target="_blank">10852086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-35339194">
<a name="35339194"></a>Dorji C, Robin FA, Na-Bangchang K. Omeprazole-induced galactorrhea in kidney transplant patients-a case report. <i>J Med Case Rep</i>. 2022;16(1):121. doi:10.1186/s13256-022-03337-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/35339194/pubmed" id="35339194" target="_blank">35339194</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31817776">
<a name="31817776"></a>Douwes RM, Gomes-Neto AW, Schutten JC, et al. Proton-pump inhibitors and hypomagnesaemia in kidney transplant recipients. <i>J Clin Med</i>. 2019;8(12):2162. doi:10.3390/jcm8122162<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31817776/pubmed" id="31817776" target="_blank">31817776</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36194028">
<a name="36194028"></a>Dunbar K, Yadlapati R, Konda V. Heartburn, nausea, and vomiting during pregnancy. <i>Am J Gastroenterol</i>. 2022;117(10S):10-15. doi:10.14309/ajg.0000000000001958<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/36194028/pubmed" id="36194028" target="_blank">36194028</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29915158">
<a name="29915158"></a>Eichenwald EC, Committee on Fetus and Newborn. Diagnosis and management of gastroesophageal reflux in preterm infants. <i>Pediatrics</i>. 2018;142(1). pii: e20181061.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/29915158/pubmed" id="29915158" target="_blank">29915158</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15447744">
<a name="15447744"></a>El-Serag HB, Aguirre TV, Davis S, Kuebeler M, Bhattacharyya A, Sampliner RE. Proton pump inhibitors are associated with reduced incidence of dysplasia in Barrett's esophagus. <i>Am J Gastroenterol</i>. 2004;99(10):1877-1883. doi: 10.1111/j.1572-0241.2004.30228.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/15447744/pubmed" id="15447744" target="_blank">15447744</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29582462">
<a name="29582462"></a>Elosua-González M, Campos-Domínguez M, Bancalari D, et al. Omeprazole-induced hypertrichosis in two children. <i>Pediatr Dermatol</i>. 2018;35(4):e212-e214. doi:10.1111/pde.13496<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/29582462/pubmed" id="29582462" target="_blank">29582462</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22314213">
<a name="22314213"></a>Erichsen R, Mikkelsen E, Pedersen L, Sørensen HT. Maternal use of proton pump inhibitors during early pregnancy and the prevalence of hypospadias in male offspring. <i>Am J Ther.</i> 2014;21(4):254-259. doi: 10.1097/MJT.0b013e3182456a8f<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22314213/pubmed" id="22314213" target="_blank">22314213</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-34605781">
<a name="34605781"></a>Evans L, Rhodes A, Alhazzani W, et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021. <i>Crit Care Med</i>. 2021;49(11):e1063-e1143<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/34605781/pubmed" id="34605781" target="_blank">34605781</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2386275">
<a name="2386275"></a>Ewart MC, Yau G, Gin T, Kotur CF, Oh TE. A comparison of the effects of omeprazole and ranitidine on gastric secretion in women undergoing elective caesarean section. <i>Anaesthesia</i>. 1990;45(7):527-530. doi: 10.1111/j.1365-2044.1990.tb14823.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/2386275/pubmed" id="2386275" target="_blank">2386275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27102658">
<a name="27102658"></a>Fallone CA, Chiba N, van Zanten SV, et al. The Toronto consensus for the treatment of <i>Helicobacter pylori</i> infection in adults. <i>Gastroenterology.</i> 2016;151(1):51-69.e14. doi: 10.1053/j.gastro.2016.04.006<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/27102658/pubmed" id="27102658" target="_blank">27102658</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22800870">
<a name="22800870"></a>Famularo G, Minisola G, Bravi MC, Colucci P, Gasbarrone L. Tetany, hypomagnesemia, and proton-pump inhibitors. <i>Am J Med</i>. 2012;125(10):e7-e8. doi:10.1016/j.amjmed.2012.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22800870/pubmed" id="22800870" target="_blank">22800870</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Fass.2019">
<a name="Fass.2019"></a>Fass R. Approach to refractory gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 7, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-FDA.2011">
<a name="FDA.2011"></a>FDA Drug Safety Communication. Low magnesium levels can be associated with long-term use of Proton Pump Inhibitor drugs (PPIs). <a href="https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump" target="_blank">https://www.fda.gov/drugs/drug-safety-and-availability/fda-drug-safety-communication-low-magnesium-levels-can-be-associated-long-term-use-proton-pump</a>. March 2, 2011.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.2019b">
<a name="Feldman.2019b"></a>Feldman M. NSAIDs (including aspirin): Secondary prevention of gastroduodenal toxicity. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed August 28, 2019b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Feldman.2021a">
<a name="Feldman.2021a"></a>Feldman M, Das S. NSAIDs (including aspirin): Primary prevention of gastroduodenal toxicity. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10201459">
<a name="10201459"></a>Festen HP, Schenk E, Tan G, Snel P, Nelis F; Dutch Reflux Study Group. Omeprazole versus high-dose ranitidine in mild gastroesophageal reflux disease: short- and long-term treatment. <i>Am J Gastroentero</i>l. 1999;94(4):931-936. doi: 10.1111/j.1572-0241.1999.989_l.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10201459/pubmed" id="10201459" target="_blank">10201459</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32092686">
<a name="32092686"></a>Fontecha-Barriuso M, Martín-Sanchez D, Martinez-Moreno JM, et al. Molecular pathways driving omeprazole nephrotoxicity. <i>Redox Biol</i>. 2020;32:101464. doi:10.1016/j.redox.2020.101464<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32092686/pubmed" id="32092686" target="_blank">32092686</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25986385">
<a name="25986385"></a>Freedberg DE, Haynes K, Denburg MR, et al. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study. <i>Osteoporos Int</i>. 2015;26(10):2501-2507. doi:10.1007/s00198-015-3168-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/25986385/pubmed" id="25986385" target="_blank">25986385</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2007355">
<a name="2007355"></a>Frucht H, Maton PN, Jensen RT. Use of omeprazole in patients with Zollinger-Ellison syndrome. <i>Dig Dis Sci</i>. 1991;36(4):394-404. doi: 10.1007/bf01298865<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/2007355/pubmed" id="2007355" target="_blank">2007355</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9988207">
<a name="9988207"></a>Galindo PA, Borja J, Feo F, et al. Anaphylaxis to omeprazole. <i>Ann Allergy Asthma Immunol</i>. 1999;82(1):52-54. doi:10.1016/S1081-1206(10)62660-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9988207/pubmed" id="9988207" target="_blank">9988207</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20461972">
<a name="20461972"></a>Gázquez V, Dalmau G, Gaig P, Gómez C, Navarro S, Mercé J. Kounis syndrome: report of 5 cases. <i>J Investig Allergol Clin Immunol</i>. 2010;20(2):162-165.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20461972/pubmed" id="20461972" target="_blank">20461972</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16630752">
<a name="16630752"></a>Geevasinga N, Coleman PL, Webster AC, Roger SD. Proton pump inhibitors and acute interstitial nephritis. <i>Clin Gastroenterol Hepatol</i>. 2006;4(5):597-604. doi:10.1016/j.cgh.2005.11.004<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/16630752/pubmed" id="16630752" target="_blank">16630752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16630752">
<a name="16630752"></a>Gomm W, von Holt K, Thomé F, et al. Association of proton pump inhibitors with risk of dementia: a pharmacoepidemiological claims data analysis. <i>JAMA Neurol</i>. 2016;73(4):410-416. doi:10.1001/jamaneurol.2015.4791<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/16630752/pubmed" id="16630752" target="_blank">16630752</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26794837">
<a name="26794837"></a>González-Rubio F, Esteban-Jiménez O, Garcés-Sotillos MD, Colás-Sanz C. Anaphylactic shock due to omeprazole. Shock anafiláctico por omeprazol. <i>Gastroenterol Hepatol</i>. 2017;40(1):20-21. doi:10.1016/j.gastrohep.2015.11.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/26794837/pubmed" id="26794837" target="_blank">26794837</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20586518">
<a name="20586518"></a>Gouraud A, Vochelle V, Descotes J, Vial T. Proton pump inhibitor-induced neutropenia: possible cross-reactivity between omeprazole and pantoprazole. <i>Clin Drug Investig</i>. 2010;30(8):559-563. doi:10.2165/11537230-000000000-00000<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20586518/pubmed" id="20586518" target="_blank">20586518</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458083">
<a name="20458083"></a>Gray SL, LaCroix AZ, Larson J, et al. Proton pump inhibitor use, hip fracture, and change in bone mineral density in postmenopausal women: results from the Women's Health Initiative. <i>Arch Intern Med</i>. 2010;170(9):765-771. doi:10.1001/archinternmed.2010.94<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20458083/pubmed" id="20458083" target="_blank">20458083</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25192903">
<a name="25192903"></a>Haastrup P, Paulsen MS, Begtrup LM, Hansen JM, Jarbøl DE. Strategies for discontinuation of proton pump inhibitors: a systematic review. <i>Fam Pract</i>. 2014;31(6):625-630. doi: 10.1093/fampra/cmu050<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/25192903/pubmed" id="25192903" target="_blank">25192903</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32639541">
<a name="32639541"></a>Hall EL, Peravali R, Patel TS. Omeprazole-induced subacute cutaneous lupus erythematosus. <i>JAMA Dermatol</i>. 2020;156(9):1013. doi:10.1001/jamadermatol.2020.2415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32639541/pubmed" id="32639541" target="_blank">32639541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17635502">
<a name="17635502"></a>Härmark L, van der Wiel HE, de Groot MC, van Grootheest AC. Proton pump inhibitor-induced acute interstitial nephritis. <i>Br J Clin Pharmacol</i>. 2007;64(6):819-823. doi:10.1111/j.1365-2125.2007.02927.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/17635502/pubmed" id="17635502" target="_blank">17635502</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9494149">
<a name="9494149"></a>Hawkey CJ, Karrasch JA, Szczepañski L, et al; Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. Omeprazole compared with misoprostol for ulcers associated with nonsteroidal antiinflammatory drugs. <i>N Engl J Med</i>. 1998;338(11):727-734. doi: 10.1056/NEJM199803123381105<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9494149/pubmed" id="9494149" target="_blank">9494149</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21126704">
<a name="21126704"></a>Hershcovici T, Fass R. An algorithm for diagnosis and treatment of refractory GERD. <i>Best Pract Res Clin Gastroenterol</i>. 2010;24(6):923-936.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21126704/pubmed" id="21126704" target="_blank">21126704</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32359562">
<a name="32359562"></a>Hirano I, Chan ES, Rank MA, et al; AGA Institute Clinical Guidelines Committee; Joint Task Force on Allergy-Immunology Practice Parameters. AGA Institute and the Joint Task Force on Allergy-Immunology Practice Parameters clinical guidelines for the management of eosinophilic esophagitis. <i>Gastroenterology</i>. 2020;158(6):1776-1786. doi:10.1053/j.gastro.2020.02.038<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32359562/pubmed" id="32359562" target="_blank">32359562</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27134114">
<a name="27134114"></a>Hiransuthikul A, Rattananupong T, Klaewsongkram J, Rerknimitr P, Pongprutthipan M, Ruxrungtham K. Drug-induced hypersensitivity syndrome/drug reaction with eosinophilia and systemic symptoms (DIHS/DRESS): 11 years retrospective study in Thailand. <i>Allergol Int</i>. 2016;65(4):432-438. doi:10.1016/j.alit.2016.04.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/27134114/pubmed" id="27134114" target="_blank">27134114</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Holmes.2019">
<a name="Holmes.2019"></a>Holmes DR Jr, Sorajja P. Gastrointestinal bleeding in patients undergoing percutaneous coronary intervention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed November 7, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10065133">
<a name="10065133"></a>Holt TL, Coombes ID, Pillans PI, Scott IA. Neutropenia associated with omeprazole. <i>Med J Aust</i>. 1999;170(3):141-142.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10065133/pubmed" id="10065133" target="_blank">10065133</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29149805">
<a name="29149805"></a>Houben E, Johansson S, Nagy P, Penning-van Beest FJA, Kuipers EJ, Herings RMC. Observational cohort study: safety outcomes in children using proton pump inhibitors or histamine-2 receptor antagonists. <i>Curr Med Res Opin</i>. 2018;34(4):577-583. doi:10.1080/03007995.2017.1407302<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/29149805/pubmed" id="29149805" target="_blank">29149805</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-4065187">
<a name="4065187"></a>Howden CW, Payton CD, Meredith PA, et al. Antisecretory effect and oral pharmacokinetics of omeprazole in patients with chronic renal failure. <i>Eur J Clin Pharmacol</i>. 1985;28(6):637-640. doi:10.1007/BF00607907<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/4065187/pubmed" id="4065187" target="_blank">4065187</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20458086">
<a name="20458086"></a>Howell MD, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial <i>Clostridium difficile</i> infection. <i>Arch Intern Med</i>. 2010;170(9):784-790. doi:10.1001/archinternmed.2010.89<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20458086/pubmed" id="20458086" target="_blank">20458086</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28072858">
<a name="28072858"></a>Hu Q, Sun TT, Hong J, Fang JY, Xiong H, Meltzer SJ. Proton pump inhibitors do not reduce the risk of esophageal adenocarcinoma in patients with Barrett's esophagus: A systematic review and meta-analysis. <i>PLoS One</i>. 2017;12(1):e0169691. doi: 10.1371/journal.pone.0169691<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28072858/pubmed" id="28072858" target="_blank">28072858</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20620727">
<a name="20620727"></a>Hulot JS, Collet JP, Silvain J, et al. Cardiovascular risk in clopidogrel-treated patients according to cytochrome P450 2C19*2 loss-of-function allele or proton pump inhibitor coadministration: a systematic meta-analysis. <i>J Am Coll Cardiol</i>. 2010;56(2):134-143. doi: 10.1016/j.jacc.2009.12.071<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20620727/pubmed" id="20620727" target="_blank">20620727</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-36012913">
<a name="36012913"></a>Hussain S, Singh A, Antony B, et al. Proton pump inhibitors use and risk of preeclampsia: a meta- analysis.<i> J Clin Med</i>. 2022;11(16):4675. doi:10.3390/jcm11164675<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/36012913/pubmed" id="36012913" target="_blank">36012913</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28886621">
<a name="28886621"></a>Ibanez B, James S, Agewall S, et al; ESC Scientific Document Group. 2017 ESC guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the Management of Acute Myocardial Infarction in Patients Presenting With ST-segment Elevation of the European Society of Cardiology (ESC). <i>Eur Heart J</i>. 2018;39(2):119-177. doi: 10.1093/eurheartj/ehx393<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28886621/pubmed" id="28886621" target="_blank">28886621</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29151538">
<a name="29151538"></a>Imai R, Higuchi T, Morimoto M, Koyamada R, Okada S. Iron deficiency anemia due to the long-term use of a proton pump inhibitor. <i>Intern Med</i>. 2018;57(6):899-901. doi:10.2169/internalmedicine.9554-17<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/29151538/pubmed" id="29151538" target="_blank">29151538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9024461">
<a name="9024461"></a>"Inactive" ingredients in pharmaceutical products: update (subject review). American Academy of Pediatrics (AAP) Committee on Drugs. <i>Pediatrics</i>. 1997;99(2):268-278.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9024461/pubmed" id="9024461" target="_blank">9024461</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10891521">
<a name="10891521"></a>Ito S. Drug therapy for breast-feeding women. <i>N Engl J Med</i>. 2000;343(2):118-126. doi:10.1056/NEJM200007133430208<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10891521/pubmed" id="10891521" target="_blank">10891521</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17059515">
<a name="17059515"></a>Jalving M, Koornstra JJ, Wesseling J, Boezen HM, DE Jong S, Kleibeuker JH. Increased risk of fundic gland polyps during long-term proton pump inhibitor therapy. <i>Aliment Pharmacol Ther</i>. 2006;24(9):1341-1348. doi:10.1111/j.1365-2036.2006.03127.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/17059515/pubmed" id="17059515" target="_blank">17059515</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1553942">
<a name="1553942"></a>Jochem V, Kirkpatrick R, Greenson J, Brogan M, Sturgis T, Cook-Glenn C. Fulminant hepatic failure related to omeprazole. <i>Am J Gastroenterol</i>. 1992;87(4):523-525.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/1553942/pubmed" id="1553942" target="_blank">1553942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28541262">
<a name="28541262"></a>Jones NL, Koletzko S, Goodman K, et al. Joint ESPGHAN/NASPGHAN guidelines for the management of Helicobacter pylori in children and adolescents (update 2016). <i>J Pediatr Gastroenterol Nutr</i>. 2017;64(6):991-1003.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28541262/pubmed" id="28541262" target="_blank">28541262</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31542064">
<a name="31542064"></a>Jurakić Tončić R, Balić A, Pavičić B, et al. Occupational airborne contact dermatitis caused by omeprazole. <i>Acta Dermatovenerol Croat</i>. 2019;27(3):188-189.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31542064/pubmed" id="31542064" target="_blank">31542064</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28002471">
<a name="28002471"></a>Kaguelidou F, Alberti C, Biran V, et al. Dose-finding study of omeprazole on gastric pH in neonates with gastro-esophageal acid reflux using a bayesian sequential approach. <i>PLoS One</i>. 2016;11(12):e0166207.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28002471/pubmed" id="28002471" target="_blank">28002471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Kahrilas.2020">
<a name="Kahrilas.2020"></a>Kahrilas PJ. Medical management of gastroesophageal reflux disease in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="https://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18789939">
<a name="18789939"></a>Kahrilas PJ, Shaheen NJ, Vaezi MF, et al, “American Gastroenterological Association Medical Position Statement on the Management of Gastroesophageal Reflux Disease,” <i>Gastroenterology</i>, 2008, 135(4):1383-91.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/18789939/pubmed" id="18789939" target="_blank">18789939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18801365">
<a name="18801365"></a>Kahrilas PJ, Shaheen NJ, Vaezi MF; American Gastroenterological Association Institute; Clinical Practice and Quality Management Committee. American Gastroenterological Association Institute technical review on the management of gastroesophageal reflux disease. <i>Gastroenterology</i>. 2008;135(4):1392-1413, 1413.e1-e5.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/18801365/pubmed" id="18801365" target="_blank">18801365</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25207666">
<a name="25207666"></a>Kallam A, Singla A, Silberstein P. Proton pump induced thrombocytopenia: A case report and review of literature. <i>Platelets</i>. 2015;26(6):598-601. doi:10.3109/09537104.2014.953045<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/25207666/pubmed" id="25207666" target="_blank">25207666</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21470217">
<a name="21470217"></a>Kardaun SH, Tupker RA. Symmetrical drug-related intertriginous and flexural exanthema (Baboon syndrome) induced by omeprazole. <i>Int J Dermatol</i>. 2012;51(9):1134-1137. doi:10.1111/j.1365-4632.2010.04689.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21470217/pubmed" id="21470217" target="_blank">21470217</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23200977">
<a name="23200977"></a>Kastelein F, Spaander MC, Steyerberg EW, et al. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus. <i>Clin Gastroenterol Hepatol</i>. 2013;11(4):382-388. doi: 10.1016/j.cgh.2012.11.014<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23200977/pubmed" id="23200977" target="_blank">23200977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23419381">
<a name="23419381"></a>Katz PO, Gerson LB, Vela MF. Guidelines for the diagnosis and management of gastroesophageal reflux disease. Am J Gastroenterol. 2013 Mar;108(3):308-28; quiz 329. doi: 10.1038/ajg.2012.444. Epub 2013 Feb 19. Erratum in: Am J Gastroenterol. 2013 Oct;108(10):1672. PMID:.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23419381/pubmed" id="23419381" target="_blank">23419381</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29767318">
<a name="29767318"></a>Kim J, Blackett JW, Jodorkovsky D. Strategies for effective discontinuation of proton pump inhibitors. <i>Curr Gastroenterol Rep</i>. 2018;20(6):27. doi: 10.1007/s11894-018-0632-y<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/29767318/pubmed" id="29767318" target="_blank">29767318</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23109611">
<a name="23109611"></a>Klassen S, Krepinsky JC, Prebtani AP. Pantoprazole-induced acute interstitial nephritis. <i>CMAJ</i>. 2013;185(1):56-59. doi:10.1503/cmaj.120954<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23109611/pubmed" id="23109611" target="_blank">23109611</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32718584">
<a name="32718584"></a>Koyyada A. Long-term use of proton pump inhibitors as a risk factor for various adverse manifestations. <i>Therapie</i>. 2020;S0040-5957(20)30127-X. doi:10.1016/j.therap.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32718584/pubmed" id="32718584" target="_blank">32718584</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21626263">
<a name="21626263"></a>Lai HC, Hsu SW, Lu CH, et al. Anaphylaxis to pantoprazole during general anesthesia. <i>J Anesth</i>. 2011;25(4):606-608. doi:10.1007/s00540-011-1148-x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21626263/pubmed" id="21626263" target="_blank">21626263</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-33929377">
<a name="33929377"></a>Laine L, Barkun AN, Saltzman JR, Martel M, Leontiadis GI. ACG clinical guideline: upper gastrointestinal and ulcer bleeding. <i>Am J Gastroenterol</i>. 2021;116(5):899-917. doi:10.14309/ajg.0000000000001245<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/33929377/pubmed" id="33929377" target="_blank">33929377</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24327038">
<a name="24327038"></a>Lam JR, Schneider JL, Zhao W, Corley DA. Proton pump inhibitor and histamine 2 receptor antagonist use and vitamin B12 deficiency. <i>JAMA</i>. 2013;310(22):2435-2442. doi:10.1001/jama.2013.280490<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24327038/pubmed" id="24327038" target="_blank">24327038</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19240698">
<a name="19240698"></a>Lanza FL, Chan FK, Quigley EM; Practice Parameters Committee of the American College of Gastroenterology. Guidelines for prevention of NSAID-related ulcer complications. <i>Am J Gastroenterol</i>. 2009;104(3):728-738. doi: 10.1038/ajg.2009.115<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/19240698/pubmed" id="19240698" target="_blank">19240698</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1624174">
<a name="1624174"></a>Larner AJ, Lendrum R. Oesophageal candidiasis after omeprazole therapy. <i>Gut</i>. 1992;33(6):860-861. doi:10.1136/gut.33.6.860<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/1624174/pubmed" id="1624174" target="_blank">1624174</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32677040">
<a name="32677040"></a>Laserna-Mendieta EJ, Casabona S, Guagnozzi D, et al; EUREOS EoE CONNECT research group. Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry. <i>Aliment Pharmacol Ther</i>. 2020;52(5):798-807. doi:10.1111/apt.15957<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32677040/pubmed" id="32677040" target="_blank">32677040</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26752337">
<a name="26752337"></a>Lazarus B, Chen Y, Wilson FP, et al. Proton pump inhibitor use and the risk of chronic kidney disease. <i>JAMA Intern Med</i>. 2016:238-246.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/26752337/pubmed" id="26752337" target="_blank">26752337</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8652333">
<a name="8652333"></a>Levack ID, Bowie RA, Braid DP, et al. Comparison of the effect of two dose schedules of oral omeprazole with oral ranitidine on gastric aspirate pH and volume in patients undergoing elective surgery. <i>Br J Anaesth</i>. 1996;76(4):567-569. doi: 10.1093/bja/76.4.567<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/8652333/pubmed" id="8652333" target="_blank">8652333</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22064601">
<a name="22064601"></a>Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” <i>Circulation</i>, 2011, 124(23):e574-651.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22064601/pubmed" id="22064601" target="_blank">22064601</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9201091">
<a name="9201091"></a>Levy MJ, Seelig CB, Robinson NJ, Ranney JE. Comparison of omeprazole and ranitidine for stress ulcer prophylaxis. <i>Dig Dis Sci.</i> 1997;42(6):1255-1259. doi: 10.1023/a:1018810325370<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9201091/pubmed" id="9201091" target="_blank">9201091</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29245331">
<a name="29245331"></a>Li B, Ma H, Wang Z, Liu L. When omeprazole met with asymptomatic Clostridium difficile colonization in a postoperative colon cancer patient: A case report. <i>Medicine (Baltimore)</i>. 2017;96(49):e9089. doi:10.1097/MD.0000000000009089<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/29245331/pubmed" id="29245331" target="_blank">29245331</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28658503">
<a name="28658503"></a>Lin CY, Wang CW, Hui CR, et al. Delayed-type hypersensitivity reactions induced by proton pump inhibitors: A clinical and in vitro T-cell reactivity study. <i>Allergy</i>. 2018;73(1):221-229. doi:10.1111/all.13235<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28658503/pubmed" id="28658503" target="_blank">28658503</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23629618">
<a name="23629618"></a>Lightdale JR, Gremse DA, and the Section on Gastroenterology, Hepatology, and Nutrition," Gastroesophageal Reflux: Management Guidance for the Pediatrician," <i>Pediatrics</i>, 2013, 131(5):e1684-95.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23629618/pubmed" id="23629618" target="_blank">23629618</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19274931">
<a name="19274931"></a>Lobera T, Navarro B, Del Pozo MD, et al. Nine cases of omeprazole allergy: cross-reactivity between proton pump inhibitors. <i>J Investig Allergol Clin Immunol</i>. 2009;19(1):57-60.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/19274931/pubmed" id="19274931" target="_blank">19274931</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Longstreth.2022">
<a name="Longstreth.2022"></a>Longstreth GF, Lacy BE. Functional dyspepsia in adults. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Losec.1">
<a name="Losec.1"></a>Losec (omeprazole) [product monograph]. Mississauga, Ontario, Canada: Xediton Pharmaceuticals Inc; May 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26247167">
<a name="26247167"></a>Lucendo AJ, Arias Á, Molina-Infante J. Efficacy of proton pump inhibitor drugs for inducing clinical and histologic remission in patients with symptomatic esophageal eosinophilia: a systematic review and meta-analysis. <i>Clin Gastroenterol Hepatol</i>. 2016;14(1):13-22.e1. doi:10.1016/j.cgh.2015.07.041<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/26247167/pubmed" id="26247167" target="_blank">26247167</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32058466">
<a name="32058466"></a>Lyu B, Jorgenson MR, Hansen KE, Djamali A, Astor BC. Proton pump inhibitors, but not H2-receptor antagonists, are associated with incident fractures among kidney transplant recipients. <i>Transplantation</i>. 2020;104(12):2609-2615. doi:10.1097/TP.0000000000003178<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32058466/pubmed" id="32058466" target="_blank">32058466</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20378675">
<a name="20378675"></a>Mackay JD, Bladon PT. Hypomagnesaemia due to proton-pump inhibitor therapy: a clinical case series. <i>QJM</i>. 2010;103(6):387-395. doi:10.1093/qjmed/hcq021<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20378675/pubmed" id="20378675" target="_blank">20378675</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21532230">
<a name="21532230"></a>Maeda Y, Kojima N, Araki Y, Uno T, Nishigaki K, Inaba N. Does a proton pump inhibitor cause hypokalemia? <i>Intern Med</i>. 2011;50(9):1045-1050. doi:10.2169/internalmedicine.50.4877<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21532230/pubmed" id="21532230" target="_blank">21532230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31175146">
<a name="31175146"></a>Malchodi L, Wagner K, Susi A, Gorman G, Hisle-Gorman E. Early acid suppression therapy exposure and fracture in young children. <i>Pediatrics</i>. 2019;144(1):e20182625.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31175146/pubmed" id="31175146" target="_blank">31175146</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10621892">
<a name="10621892"></a>Mamun M, Caddick S, Siddiqi MA. Omeprazole and excessive sweating, if unrecognised, may lead to unnecessary investigations. <i>Postgrad Med J</i>. 1999;75(889):701-702. doi:10.1136/pgmj.75.889.701<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10621892/pubmed" id="10621892" target="_blank">10621892</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8789905">
<a name="8789905"></a>Markitziu A, Aframian D. Side effects of omeprazole. <i>Scand J Gastroenterol</i>. 1996;31(6):624. doi:10.3109/00365529609009139<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/8789905/pubmed" id="8789905" target="_blank">8789905</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-1992636">
<a name="1992636"></a>Marks DR, Joy JV, Bonheim NA. Hemolytic anemia associated with the use of omeprazole. <i>Am J Gastroenterol</i>. 1991;86(2):217-218.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/1992636/pubmed" id="1992636" target="_blank">1992636</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9582548">
<a name="9582548"></a>Marshall JK, Thompson AB, Armstrong D. Omeprazole for refractory gastroesophageal reflux disease during pregnancy and lactation. <i>Can J Gastroenterol.</i> 1998;12(3):225-227. doi:10.1155/1998/167174<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9582548/pubmed" id="9582548" target="_blank">9582548</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22038541">
<a name="22038541"></a>Matok I, Levy A, Wiznitzer A, et al, "The Safety of Fetal Exposure to Proton-Pump Inhibitors During Pregnancy," <i>Dig Dis Sci</i>, 2012, 57(3):699-705.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22038541/pubmed" id="22038541" target="_blank">22038541</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-2575060">
<a name="2575060"></a>Meijer JL, Jansen JB, Lamers CB. Omeprazole in the treatment of Zollinger-Ellison syndrome and histamine H2-antagonist refractory ulcers. <i>Digestion</i>. 1989;44(suppl 1):31-39. doi: 10.1159/000200102<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/2575060/pubmed" id="2575060" target="_blank">2575060</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28717077">
<a name="28717077"></a>Miyamoto S, Kato M, Matsuda K, et al. Gastric hyperplastic polyps associated with proton pump inhibitor use in a case without a history of <i>Helicobacter pylori</i> infection. <i>Intern Med</i>. 2017;56(14):1825-1829. doi:10.2169/internalmedicine.56.8040<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28717077/pubmed" id="28717077" target="_blank">28717077</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31152740">
<a name="31152740"></a>Moayyedi P, Eikelboom JW, Bosch J, et al. Safety of proton pump inhibitors based on a large, multi-year, randomized trial of patients receiving rivaroxaban or aspirin. <i>Gastroenterology</i>. 2019;157(3):682-691.e2. doi:10.1053/j.gastro.2019.05.056<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31152740/pubmed" id="31152740" target="_blank">31152740</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28631728">
<a name="28631728"></a>Moayyedi PM, Lacy BE, Andrews CN, Enns RA, Howden CW, Vakil N. ACG and CAG clinical guideline: management of dyspepsia. <i>Am J Gastroenterol</i>. 2017;112(7):988-1013. doi: 10.1038/ajg.2017.154<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28631728/pubmed" id="28631728" target="_blank">28631728</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24927897">
<a name="24927897"></a>Muriithi AK, Leung N, Valeri AM, et al. Biopsy-proven acute interstitial nephritis, 1993-2011: a case series. <i>Am J Kidney Dis</i>. 2014;64(4):558-566. doi:10.1053/j.ajkd.2014.04.027<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24927897/pubmed" id="24927897" target="_blank">24927897</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11774962">
<a name="11774962"></a>Myers RP, McLaughlin K, Hollomby DJ. Acute interstitial nephritis due to omeprazole. <i>Am J Gastroenterol</i>. 2001;96(12):3428-3431. doi:10.1111/j.1572-0241.2001.05345.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11774962/pubmed" id="11774962" target="_blank">11774962</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25323274">
<a name="25323274"></a>Nadri Q, Althaf MM. Granulomatous tubulointerstitial nephritis secondary to omeprazole. <i>BMJ Case Rep</i>. 2014;2014:bcr2014203842. doi:10.1136/bcr-2014-203842<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/25323274/pubmed" id="25323274" target="_blank">25323274</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-3742939">
<a name="3742939"></a>Naesdal J, Andersson T, Bodemar G, et al. Pharmacokinetics of [14C]omeprazole in patients with impaired renal function. <i>Clin Pharmacol Ther</i>. 1986;40(3):344-351. doi:10.1038/clpt.1986.186<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/3742939/pubmed" id="3742939" target="_blank">3742939</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30237993">
<a name="30237993"></a>Nassar Y, Richter S. Proton-pump inhibitor use and fracture risk: an updated systematic review and meta-analysis. <i>J Bone Metab</i>. 2018;25(3):141-151. doi:10.11005/jbm.2018.25.3.141<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/30237993/pubmed" id="30237993" target="_blank">30237993</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-NICE.2014">
<a name="NICE.2014"></a>National Institute for Health and Care Excellence. Drug allergy: diagnosis and management. Clinical guideline [CG183]. https://www.nice.org.uk/guidance/cg183. September 3, 2014.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10772433">
<a name="10772433"></a>Natsch S, Vinks MH, Voogt AK, et al, “Anaphylactic Reactions to Proton-Pump Inhibitors,” <i>Ann Pharmacother</i>, 2000, 34(4):474-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10772433/pubmed" id="10772433" target="_blank">10772433</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21143456">
<a name="21143456"></a>Ni N, Moeckel GW, Kumar C. Late-onset omeprazole-associated acute interstitial nephritis. <i>J Am Geriatr Soc</i>. 2010;58(12):2443-2444. doi:10.1111/j.1532-5415.2010.03194.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21143456/pubmed" id="21143456" target="_blank">21143456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19523538">
<a name="19523538"></a>Nguyen DM, El-Serag HB, Henderson L, Stein D, Bhattacharyya A, Sampliner RE. Medication usage and the risk of neoplasia in patients with Barrett's esophagus. <i>Clin Gastroenterol Hepatol</i>. 2009;7(12):1299-1304. doi: 10.1016/j.cgh.2009.06.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/19523538/pubmed" id="19523538" target="_blank">19523538</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25112692">
<a name="25112692"></a>Nylund CM, Eide M, Gorman GH. Association of Clostridium difficile infections with acid suppression medications in children. <i>J Pediatr</i>. 2014;165(5):979-984.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/25112692/pubmed" id="25112692" target="_blank">25112692</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10583693">
<a name="10583693"></a>Odou P, Martin P, Membré S, et al. Omeprazole-induced leukopenia. A case report. <i>J Clin Pharm Ther</i>. 1999;24(5):317-321. doi:10.1046/j.1365-2710.1999.00240.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10583693/pubmed" id="10583693" target="_blank">10583693</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17204951">
<a name="17204951"></a>Omari TI, Haslam RR, Lundborg P, et al, "Effect of Omeprazole on Acid Gastroesophageal Reflux and Gastric Acidity in Preterm Infants With Pathological Acid Reflux," <i>J Pediatr Gastroenterol Nutr</i>, 2007, 44(1):41-4.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/17204951/pubmed" id="17204951" target="_blank">17204951</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apotex.1">
<a name="Apotex.1"></a>Omeprazole delayed-release capsules [prescribing information]. Weston, FL: Apotex Corp; May 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-GeriCare.1">
<a name="GeriCare.1"></a>Omeprazole Magnesium [prescribing information]. Brooklyn, NY: Geri-Care Pharmaceuticals Corp; received February 2016.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7789474">
<a name="7789474"></a>Ottervanger JP, Stricker BH, Kappelle JW, Claas FH. Omeprazole-associated agranulocytosis. <i>Eur J Haematol</i>. 1995;54(4):279-280. doi:10.1111/j.1600-0609.1995.tb00686.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/7789474/pubmed" id="7789474" target="_blank">7789474</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23455632">
<a name="23455632"></a>Ozdil K, Kahraman R, Sahin A, et al. Bone density in proton pump inhibitors users: a prospective study. <i>Rheumatol Int</i>. 2013;33(9):2255-2260. doi:10.1007/s00296-013-2709-0<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23455632/pubmed" id="23455632" target="_blank">23455632</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31187275">
<a name="31187275"></a>Park YH, Seong JM, Cho S, et al. Effects of proton pump inhibitor use on risk of <i>Clostridium difficile</i> infection: a hospital cohort study. <i>J Gastroenterol</i>. 2019;54(12):1052-1060. doi:10.1007/s00535-019-01598-2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31187275/pubmed" id="31187275" target="_blank">31187275</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37269915">
<a name="37269915"></a>Peron A, Ripoche E, Picot C, Ajiji P, Cucherat M, Cottin J. Use of proton pump inhibitors during pregnancy: a systematic review and meta-analysis of congenital malformations. <i>Reprod Toxicol</i>. 2023;119:108419. doi:10.1016/j.reprotox.2023.108419<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/37269915/pubmed" id="37269915" target="_blank">37269915</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8917027">
<a name="8917027"></a>Phillips JO, Metzler MH, Palmieri MT, et al, "A Prospective Study of Simplified Omeprazole Suspension for the Prophylaxis of Stress-Related Mucosal Damage," <i>Crit Care Med</i>, 1996, 24(11):1793-800.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/8917027/pubmed" id="8917027" target="_blank">8917027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26939578">
<a name="26939578"></a>Philpott H, Nandurkar S, Royce SG, Thien F, Gibson PR. A prospective open clinical trial of a proton pump inhibitor, elimination diet and/or budesonide for eosinophilic oesophagitis. <i>Aliment Pharmacol Ther</i>. 2016;43(9):985-993. doi:10.1111/apt.13576<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/26939578/pubmed" id="26939578" target="_blank">26939578</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28271513">
<a name="28271513"></a>Pinto-Sanchez MI, Yuan Y, Bercik P, Moayyedi P. Proton pump inhibitors for functional dyspepsia [published update appears in <i>Cochrane Database Syst Rev</i>. 2017;11:CD011194]. <i>Cochrane Database Syst Rev</i>. 2017;3:CD011194. doi: 10.1002/14651858.CD011194.pub2<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28271513/pubmed" id="28271513" target="_blank">28271513</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28325163">
<a name="28325163"></a>Prag C, Prag M, Fredlund H. Proton pump inhibitors as a risk factor for norovirus infection. <i>Epidemiol Infect</i>. 2017;145(8):1617-1623. doi:10.1017/S0950268817000528<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28325163/pubmed" id="28325163" target="_blank">28325163</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prilosec.1">
<a name="Prilosec.1"></a>Prilosec (omeprazole magnesium) for delayed-release oral suspension [prescribing information]. AstraZeneca group companies; March 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prilosec.1">
<a name="Prilosec.1"></a>Prilosec (omeprazole magnesium) for delayed-release oral suspension [prescribing information]. AstraZeneca group companies; July 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Prilosec.2">
<a name="Prilosec.2"></a>Prilosec OTC (omeprazole) [prescribing information]. Cincinnati, OH: Procter &amp; Gamble; received October 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-PAD.2015">
<a name="PAD.2015"></a>Province of British Columbia Ministry of Health. Proton pump inhibitors in primary care. BC Provincial Academic Detailing (PAD) Service. <a href="https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/provincial-academic-detailing-service/pad-2015-proton-pump-inhibitors-newsletter.pdf" target="_blank">https://www2.gov.bc.ca/assets/gov/health/practitioner-pro/provincial-academic-detailing-service/pad-2015-proton-pump-inhibitors-newsletter.pdf</a>. Published January 2015. Accessed August 22, 2019.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22289674">
<a name="22289674"></a>Puig I, Calzado S, Suárez D, Sánchez-Delgado J, López S, Calvet X. Meta-analysis: comparative efficacy of H2-receptor antagonists and proton pump inhibitors for reducing aspiration risk during anaesthesia depending on the administration route and schedule. <i>Pharmacol Res</i>. 2012;65(4):480-490. doi: 10.1016/j.phrs.2012.01.005<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/22289674/pubmed" id="22289674" target="_blank">22289674</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29610598">
<a name="29610598"></a>Qorraj-Bytyqi H, Hoxha R, Sadiku S, et al. Proton pump inhibitors intake and iron and vitamin B12 status: a prospective comparative study with a follow up of 12 months. <i>Open Access Maced J Med Sci</i>. 2018;6(3):442-446. doi:10.3889/oamjms.2018.142<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/29610598/pubmed" id="29610598" target="_blank">29610598</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21930865">
<a name="21930865"></a>Quasdorff M, Mertens J, Dinter J, Steffen HM. Recurrent hypomagnesemia with proton-pump inhibitor rechallenge. <i>Ann Intern Med</i>. 2011;155(6):405-407. doi:10.7326/0003-4819-155-6-201109200-00022<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21930865/pubmed" id="21930865" target="_blank">21930865</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9269520">
<a name="9269520"></a>Quercia R, Fan C, Liu X, et al, “Stability of Omeprazole in an Extemporaneously Prepared Oral Liquid,” <i>Am J Health Syst Pharm</i>, 1997, 54(16):1833-6.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9269520/pubmed" id="9269520" target="_blank">9269520</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12095478">
<a name="12095478"></a>Ramakrishnan A, Katz PO. Pharmacologic management of gastroesophageal reflux disease. <i>Curr Treat Options Gastroenterol</i>. 2002;5(4):301-310. doi: 10.1007/s11938-002-0053-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/12095478/pubmed" id="12095478" target="_blank">12095478</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9692668">
<a name="9692668"></a>Rebuck JA, Rybak MJ, Ramos DP, Weingarten CM. Omeprazole-induced exfoliative dermatitis. <i>Pharmacotherapy</i>. 1998;18(4):877-879.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9692668/pubmed" id="9692668" target="_blank">9692668</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16817839">
<a name="16817839"></a>Regula J, Butruk E, Dekkers CP, et al. Prevention of NSAID-associated gastrointestinal lesions: a comparison study pantoprazole versus omeprazole. <i>Am J Gastroenterol</i>. 2006;101(8):1747-1755. doi: 10.1111/j.1572-0241.2006.00686.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/16817839/pubmed" id="16817839" target="_blank">16817839</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28101605">
<a name="28101605"></a>Rhodes A, Evans LE, Alhazzani W, et al. Surviving Sepsis Campaign: international guidelines for management of sepsis and septic shock: 2016. <i>Intensive Care Med.</i> 2017;43(3):304-377. doi: 10.1007/s00134-017-4683-6<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28101605/pubmed" id="28101605" target="_blank">28101605</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30792587">
<a name="30792587"></a>Ribeiro RHT, Ribeiro FA, Silva RPM, Bortolini MJS, Garrote-Filho MDS, Penha-Silva N. Depression, hematologic parameters, and blood levels of vitamin B<sub>12</sub> in patients with laryngopharyngeal reflux under use of proton pump inhibitors. <i>Clin Med Insights Ear Nose Throat</i>. 2019;12:1179550619828683. doi:10.1177/1179550619828683<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/30792587/pubmed" id="30792587" target="_blank">30792587</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30051945">
<a name="30051945"></a>Rodríguez-Martín S, Martín-Merino E, Lerma V, et al. Active surveillance of severe cutaneous adverse reactions: A case-population approach using a registry and a health care database. <i>Pharmacoepidemiol Drug Saf</i>. 2018;27(9):1042-1050. doi:10.1002/pds.4622<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/30051945/pubmed" id="30051945" target="_blank">30051945</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-29470322">
<a name="29470322"></a>Rosen R, Vandenplas Y, Singendonk M, et al. Pediatric gastroesophageal reflux clinical practice guidelines: joint recommendations of the North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition and the European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. <i>J Pediatr Gastroenterol Nutr</i>. 2018;66(3):516-554.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/29470322/pubmed" id="29470322" target="_blank">29470322</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Saltzman.2022">
<a name="Saltzman.2022"></a>Saltzman JR. Overview of the treatment of bleeding peptic ulcers. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed June 6, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23960351">
<a name="23960351"></a>Sampathkumar K, Ramalingam R, Prabakar A, Abraham A. Acute interstitial nephritis due to proton pump inhibitors. <i>Indian J Nephrol</i>. 2013;23(4):304-307. doi:10.4103/0971-4065.114487<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/23960351/pubmed" id="23960351" target="_blank">23960351</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24834779">
<a name="24834779"></a>Sánchez-Morillas L, Rojas Pérez-Ezquerra P, González Mendiola R, Gómez-Tembleque Ubeda P, Santos Alvarez A, Laguna-Martínez JJ. Eleven cases of omeprazole hypersensitivity: diagnosis and study of cross-reactivity. <i>J Investig Allergol Clin Immunol</i>. 2014;24(2):130-132.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24834779/pubmed" id="24834779" target="_blank">24834779</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24547721">
<a name="24547721"></a>Sandholdt LH, Laurinaviciene R, Bygum A. Proton pump inhibitor-induced subacute cutaneous lupus erythematosus. <i>Br J Dermatol</i>. 2014;170(2):342-351. doi:10.1111/bjd.12699<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24547721/pubmed" id="24547721" target="_blank">24547721</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9224084">
<a name="9224084"></a>Schönhöfer PS, Werner B, Tröger U. Ocular damage associated with proton pump inhibitors. <i>BMJ</i>. 1997;314(7097):1805. doi:10.1136/bmj.314.7097.1805<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9224084/pubmed" id="9224084" target="_blank">9224084</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28625416">
<a name="28625416"></a>Sebastián Domingo JJ. Omeprazole-induced hallucinations. Not as rare as you might think. Alucinaciones por omeprazol. No tan raras como se cree. <i>Gastroenterol Hepatol</i>. 2018;41(4):266-267. doi:10.1016/j.gastrohep.2017.05.002<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28625416/pubmed" id="28625416" target="_blank">28625416</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18617497">
<a name="18617497"></a>Shabajee N, Lamb EJ, Sturgess I, Sumathipala RW. Omeprazole and refractory hypomagnesaemia. <i>BMJ</i>. 2008;337(7662):a425. doi:10.1136/bmj.39505.738981.BE<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/18617497/pubmed" id="18617497" target="_blank">18617497</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-26526079">
<a name="26526079"></a>Shaheen NJ, Falk GW, Iyer PG, Gerson LB; American College of Gastroenterology. ACG clinical guideline: diagnosis and management of Barrett's esophagus. <i>Am J Gastroenterol</i>. 2016;111(1):30-50. doi: 10.1038/ajg.2015.322<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/26526079/pubmed" id="26526079" target="_blank">26526079</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32128193">
<a name="32128193"></a>Sharma N, Ip R, Hadid T. Concomitant acute interstitial nephritis and autoimmune hemolytic anemia induced by omeprazole. <i>Clin Case Rep</i>. 2020;8(2):379-382. doi:10.1002/ccr3.2661<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32128193/pubmed" id="32128193" target="_blank">32128193</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10597120">
<a name="10597120"></a>Sharma V, “Comparison of 24-hour Intragastric pH Using Four Liquid Formulations of Lansoprazole and Omeprazole,” <i>Am J Health Syst Pharm</i>, 1999, 56(23 Suppl 4):18-21.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10597120/pubmed" id="10597120" target="_blank">10597120</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-21365243">
<a name="21365243"></a>Sheen E, Triadafilopoulos G. Adverse effects of long-term proton pump inhibitor therapy. <i>Dig Dis Sci</i>. 2011;56(4):931-950. doi:10.1007/s10620-010-1560-3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/21365243/pubmed" id="21365243" target="_blank">21365243</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8769288">
<a name="8769288"></a>Shiba S, Sugiura K, Ebata A, et al. Hyponatremia with consciousness disturbance caused by omeprazole administration. A case report and literature review. <i>Dig Dis Sci</i>. 1996;41(8):1615-1617. doi:10.1007/BF02087909<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/8769288/pubmed" id="8769288" target="_blank">8769288</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24221456">
<a name="24221456"></a>Singh S, Garg SK, Singh PP, Iyer PG, El-Serag HB. Acid-suppressive medications and risk of oesophageal adenocarcinoma in patients with Barrett's oesophagus: a systematic review and meta-analysis. <i>Gut</i>. 2014;63(8):1229-1237. doi: 10.1136/gutjnl-2013-305997<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24221456/pubmed" id="24221456" target="_blank">24221456</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11329761">
<a name="11329761"></a>Song JC, Quercia RA, Fan C, et al, "Pharmacokinetic Comparison of Omeprazole Capsules and a Simplified Omeprazole Suspension," <i>Am J Health Syst Pharm</i>, 2001, 58(8):689-94.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11329761/pubmed" id="11329761" target="_blank">11329761</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7797283">
<a name="7797283"></a>Sood A, Sharma M, Jain NP, Chawla LS, Kumar R. Esophageal candidiasis following omeprazole therapy: a report of two cases. <i>Indian J Gastroenterol</i>. 1995;14(2):71-72.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/7797283/pubmed" id="7797283" target="_blank">7797283</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Spechler.2019">
<a name="Spechler.2019"></a>Spechler SJ. Barrett's esophagus: Surveillance and management. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25162890">
<a name="25162890"></a>Spechler SJ, Souza RF. Barrett's esophagus. <i>N Engl J Med</i>. 2014;371(9):836-845. doi: 10.1056/NEJMra1314704.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/25162890/pubmed" id="25162890" target="_blank">25162890</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-18695179">
<a name="18695179"></a>Targownik LE, Lix LM, Metge CJ, Prior HJ, Leung S, Leslie WD. Use of proton pump inhibitors and risk of osteoporosis-related fractures. <i>CMAJ</i>. 2008;179(4):319-326. doi:10.1503/cmaj.071330<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/18695179/pubmed" id="18695179" target="_blank">18695179</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-7770709">
<a name="7770709"></a>Teare JP, Spedding C, Whitehead MW, Greenfield SM, Challacombe SJ, Thompson RP. Omeprazole and dry mouth. <i>Scand J Gastroenterol</i>. 1995;30(3):216-218. doi:10.3109/00365529509093266<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/7770709/pubmed" id="7770709" target="_blank">7770709</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9626024">
<a name="9626024"></a>Termanini B, Gibril F, Sutliff VE, Yu F, Venzon DJ, Jensen RT. Effect of long-term gastric acid suppressive therapy on serum vitamin B12 levels in patients with Zollinger-Ellison syndrome. <i>Am J Med</i>. 1998;104(5):422-430. doi:10.1016/s0002-9343(98)00087-4<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9626024/pubmed" id="9626024" target="_blank">9626024</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19659985">
<a name="19659985"></a>Thakor AS, Burke A, Handfield-Jones S, Sinha A, Palmer M, Burns A. Toxic epidermal necrolysis and neutropaenia: complications of omeprazole. <i>Australas J Dermatol</i>. 2009;50(3):207-210. doi:10.1111/j.1440-0960.2009.00540.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/19659985/pubmed" id="19659985" target="_blank">19659985</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31950535">
<a name="31950535"></a>Thélin CS, Richter JE. Review article: the management of heartburn during pregnancy and lactation. <i>Aliment Pharmacol Ther</i>. 2020;51(4):421-434. doi:10.1111/apt.15611<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31950535/pubmed" id="31950535" target="_blank">31950535</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31060319">
<a name="31060319"></a>Thong BK, Ima-Nirwana S, Chin KY. Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. <i>Int J Environ Res Public Health</i>. 2019;16(9):1571. doi:10.3390/ijerph16091571<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/31060319/pubmed" id="31060319" target="_blank">31060319</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20738320">
<a name="20738320"></a>Toms-Whittle LM, John LH, Buckley DA. Drug-induced subacute cutaneous lupus erythematosus associated with omeprazole. <i>Clin Exp Dermatol</i>. 2011;36(3):281-283. doi:10.1111/j.1365-2230.2010.03926.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20738320/pubmed" id="20738320" target="_blank">20738320</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-20047577">
<a name="20047577"></a>Turco R, Martinelli M, Miele E, et al. Proton pump inhibitors as a risk factor for paediatric Clostridium difficile infection. <i>Aliment Pharmacol Ther</i>. 2010;31(7):754-759.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/20047577/pubmed" id="20047577" target="_blank">20047577</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.1">
<a name="Vakil.1"></a>Vakil NB. Approach to refractory or recurrent peptic ulcer disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020b.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.2019c">
<a name="Vakil.2019c"></a>Vakil NB. Overview of the complications of peptic ulcer disease. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 20, 2020c.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Vakil.3">
<a name="Vakil.3"></a>Vakil NB. Peptic ulcer disease: Treatment and secondary prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed July 1, 2020a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32654241">
<a name="32654241"></a>Van Tendeloo E, Gutermuth J, Grosber M. Positive patch testing with omeprazole in Stevens-Johnson syndrome: a case report. <i>J Eur Acad Dermatol Venereol</i>. 2020;10.1111/jdv.16814. doi:10.1111/jdv.16814<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32654241/pubmed" id="32654241" target="_blank">32654241</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30262672">
<a name="30262672"></a>Vangala C, Niu J, Lenihan CR, Mitch WE, Navaneethan SD, Winkelmayer WC. Proton pump inhibitors, histamine-2 receptor antagonists, and hip fracture risk among patients on hemodialysis. <i>Clin J Am Soc Nephrol</i>. 2018;13(10):1534-1541. doi:10.2215/CJN.02190218<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/30262672/pubmed" id="30262672" target="_blank">30262672</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24117619">
<a name="24117619"></a>Vazquez-Elizondo G, Ngamruengphong S, Khrisna M, Devault KR, Talley NJ, Achem SR. The outcome of patients with oesophageal eosinophilic infiltration after an eight-week trial of a proton pump inhibitor. <i>Aliment Pharmacol Ther</i>. 2013;38(10):1312-1319. doi:10.1111/apt.12513<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/24117619/pubmed" id="24117619" target="_blank">24117619</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15984968">
<a name="15984968"></a>Veldhuyzen van Zanten SJ, Chiba N, Armstrong D, et al. A randomized trial comparing omeprazole, ranitidine, cisapride, or placebo in <i>Helicobacter pylori</i> negative, primary care patients with dyspepsia: the CADET-HN Study. <i>Am J Gastroenterol</i>. 2005;100(7):1477-1488. doi: 10.1111/j.1572-0241.2005.40280.x<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/15984968/pubmed" id="15984968" target="_blank">15984968</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30094626">
<a name="30094626"></a>Waghray A, Waghray N, Perzynski AT, Votruba M, Wolfe MM. Optimal omeprazole dosing and symptom control: a randomized controlled trial (OSCAR trial). <i>Dig Dis Sci</i>. 2019;64(1):158-166. doi: 10.1007/s10620-018-5235-9<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/30094626/pubmed" id="30094626" target="_blank">30094626</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19821323">
<a name="19821323"></a>Wang Y, Pan T, Wang Q, Guo Z. Additional bedtime H2-receptor antagonist for the control of nocturnal gastric acid breakthrough. <i>Cochrane Database Syst Rev</i>. 2009;(4):CD004275. doi: 10.1002/14651858.CD004275.pub3<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/19821323/pubmed" id="19821323" target="_blank">19821323</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32176276">
<a name="32176276"></a>Wang YH, Wintzell V, Ludvigsson JF, Svanström H, Pasternak B. Association between proton pump inhibitor use and risk of fracture in children. <i>JAMA Pediatr</i>. 2020;174(6):543-551. doi:10.1001/jamapediatrics.2020.0007<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/32176276/pubmed" id="32176276" target="_blank">32176276</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28054368">
<a name="28054368"></a>Wei L, Ratnayake L, Phillips G, et al. Acid-suppression medications and bacterial gastroenteritis: a population-based cohort study. <i>Br J Clin Pharmacol</i>. 2017;83(6):1298-1308. doi:10.1111/bcp.13205<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/28054368/pubmed" id="28054368" target="_blank">28054368</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Weinhouse.2022">
<a name="Weinhouse.2022"></a>Weinhouse GL. Stress ulcers in the intensive care unit: diagnosis, management, and prevention. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 4, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19142168">
<a name="19142168"></a>Wilcox GM, Mattia AR. Microscopic colitis associated with omeprazole and esomeprazole exposure. <i>J Clin Gastroenterol</i>. 2009;43(6):551-553. doi:10.1097/MCG.0b013e31817d3fa1<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/19142168/pubmed" id="19142168" target="_blank">19142168</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wolfe.2020">
<a name="Wolfe.2020"></a>Wolfe MM. Proton pump inhibitors: Overview of use and adverse effects in the treatment of acid related disorders. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed May 7, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10868896">
<a name="10868896"></a>Wolfe MM, Sachs G. Acid suppression: optimizing therapy for gastroduodenal ulcer healing, gastroesophageal reflux disease, and stress-related erosive syndrome. <i>Gastroenterology.</i> 2000;118(2)(suppl 1):S9-S31. doi: 10.1016/s0016-5085(00)70004-7<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/10868896/pubmed" id="10868896" target="_blank">10868896</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9494148">
<a name="9494148"></a>Yeomans ND, Tulassay Z, Juhász L, et al; ASTRONAUT Study Group. A comparison of omeprazole with ranitidine for ulcers associated with nonsteroidal antiinflammatory drugs. <i>N Engl J Med</i>. 1998;338(11):719-726. doi: 10.1056/NEJM199803123381104<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9494148/pubmed" id="9494148" target="_blank">9494148</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9412948">
<a name="9412948"></a>Yip D, Kovac S, Jardine M, Horvath J, Findlay M. Omeprazole-induced interstitial nephritis. <i>J Clin Gastroenterol</i>. 1997;25(2):450-452. doi:10.1097/00004836-199709000-00011<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/9412948/pubmed" id="9412948" target="_blank">9412948</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-16372517">
<a name="16372517"></a>Youssef SS, Iskandar SB, Scruggs J, Roy TM. Acute pancreatitis associated with omeprazole. <i>Int J Clin Pharmacol Ther</i>. 2005;43(12):558-561. doi:10.5414/cpp43558<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/16372517/pubmed" id="16372517" target="_blank">16372517</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-11394727">
<a name="11394727"></a>Zimmermann AE, Walters JK, Katona BG, et al, "A Review of Omeprazole Use in the Treatment of Acid-Related Disorders in Children," <i>Clin Ther</i>, 2001, 23(5):660-79.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/omeprazole-pediatric-drug-information/abstract-text/11394727/pubmed" id="11394727" target="_blank">11394727</a>]</span>
</div>
</li></ol></div><div id="topicVersionRevision">Topic 12658 Version 772.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
